Anti-CD47 x anti-mesothelin antibodies and methods of use thereof

By developing bispecific antibodies that recognize CD47 and mesothelin, inhibiting the interaction between CD47 and SIRPα, the problem of poor toxicity and pharmacokinetics of healthy tissues when targeting CD47 in the prior art is solved, and the problem of poor toxicity and pharmacokinetics in healthy tissues is achieved. The efficient killing and therapeutic effect of cancer cells is improved.

CN111201031BActive Publication Date: 2024-11-01NOVIMMUNE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880049297.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-08-25
Filing Date
2018-05-29
Publication Date
2024-11-01
Estimated Expiration
2038-09-17

AI Technical Summary

Technical Problem

The prior art is difficult to avoid the impact on healthy tissues when targeting CD47, resulting in poor toxicity and pharmacokinetics, and the widespread expression of CD47 leads to rapid elimination of drugs, reducing therapeutic efficacy.

Method used

Develop bispecific antibodies that recognize CD47 and mesothelin, preferentially target cancer cells by inhibiting the interaction between CD47 and SIRPα, and use the design of bispecific antibodies to improve targeting and selectivity, and bind to antibody arms that bind CD47 and MSLN to Enhance affinity and selectivity.

Benefits of technology

Significantly reduce the interaction between CD47 and SIRPα, improve killing efficacy against cancer cells, enhance the selectivity and therapeutic effect of antibodies, reduce the impact on healthy tissues, and improve pharmacokinetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111201031B_ABST
    Figure CN111201031B_ABST
Patent Text Reader

Abstract

The present invention also relates to novel bispecific antibodies with a different specificity for each binding site of an immunoglobulin molecule, wherein one of the binding sites is specific for CD47 and the second binding site is specific for mesothelin (MSLN).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 511,669, filed May 26, 2017, and U.S. Provisional Application No. 62 / 550,387, filed August 25, 2017. The contents of each of these applications are incorporated herein by reference in their entirety.

[0003] INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0004] The contents of the file named "NOVI-044_001US_SequenceListing_ST25" created on May 22, 2018 and with a size of 268KB are hereby incorporated by reference in its entirety. Background of the Invention

[0006] CD47 or integrin-associated protein (IAP) is a ubiquitous 50 kDa transmembrane glycoprotein with multiple functions in cell-cell communication. It interacts with multiple ligands such as integrins, SIRPα (signal regulatory protein α), SIRPγ and thrombospondin (Oldenborg, PA, CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease, ISRN Hematol. 2013; 2013:614619; Soto-Pantoja DR, et al., Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47 (2012), Expert Opin Ther Targets. 2013 Jan;17(1):89-103; Sick E, et al., CD47 Update: a multifaceted actor in the tumor microenvironment of potential therapeutic interest, Br J Pharmacol. 2012 Dec;167(7):1415-30).

[0007] The ubiquitous expression of CD47 in healthy tissues raises questions about therapeutic safety and efficacy: First, targeting CD47 with neutralizing monoclonal antibodies (Mabs) can affect healthy tissues, leading to severe toxicity as shown in preclinical studies with mice and cynomolgus monkeys (Willingham SB, et al., Proc Natl Acad Sci US A. 2012 Apr24;109(17):6662-7; Weiskopf K, et al., Engineered SIRPα Variants as ImmunotherapeuticAdjuvants to Anticancer Antibodies, Science. 2013 Jul 5;341(6141):88-91). Second, even if severe toxicity can be avoided or mitigated by using alternative forms (Weiskopf K, et al., Science. 2013 Jul 5;341(6141):88-91), the ubiquitous expression of CD47 still causes rapid elimination of CD47 binding molecules via target-mediated drug distribution, resulting in poor pharmacokinetics and reduced efficacy.

[0008] Therefore, there is a need for antibodies and therapeutics that can target CD47 and overcome these difficulties. SUMMARY OF THE INVENTION

[0010] The present invention also provides bispecific antibodies that recognize CD47 and mesothelin. CD47 (Cluster of Differentiation 47) functions as a "don't eat me" signal for phagocytes and is known to be overexpressed by many tumors (immune escape). CD47 interacts with SIRPα (which is overexpressed on phagocytes). CD47 downregulates phagocytic activity. CD47 inhibits dendritic cell (DC) maturation and activation. CD47 is also involved in processes such as, for example, apoptosis, survival, proliferation, adhesion, migration, and regulation of angiogenesis, blood pressure, tissue perfusion, and / or platelet homeostasis.

[0011] CD47 is also involved in cancer. For example, CD47 is overexpressed in a variety of blood and solid malignancies. CD47 is a confirmed cancer stem cell / tumor initiating cell marker. It is believed that CD47 overexpression can help tumor cells escape immune surveillance and be killed by innate immune cells. High levels of CD47 are also associated with poor clinical outcomes in cancers such as, for example, leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, and / or glioma. Therefore, targeting CD47 will be useful in treating cancer symptoms, delaying the progression of cancer symptoms, or otherwise improving cancer symptoms.

[0012] Mesothelin (MSLN) is expressed at relatively low levels in normal tissues. Compared with normal tissues, mesothelin is highly expressed in several types of solid tumors such as malignant mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and endometrial cancer, biliary tract gastric cancer, and prostate cancer. Tumor mesothelin expression has been often associated with increased tumor aggressiveness and poor clinical prognosis. Therefore, targeting mesothelin will be useful in treating cancer symptoms, delaying the progression of cancer symptoms, or otherwise improving cancer symptoms.

[0013] The present invention also provides bispecific antibodies, which include at least a first arm specific for CD47. In some embodiments, the first arm is specific for at least human CD47. In some embodiments, the first arm recognizes human CD47 and is also cross-reactive for at least one other non-human CD47 protein (such as, but not limited to, non-human primate CD47, for example, cynomolgus CD47 and / or rodent CD47). In some embodiments, these anti-CD47 monoclonal antibodies inhibit the interaction between CD47 and signal regulatory protein α (SIRPα). In some embodiments, these bispecific antibodies inhibit the interaction between human CD47 and human SIRPα. The present invention also includes antibodies that bind to the same epitope as the bispecific antibodies disclosed herein and inhibit the interaction between CD47 and SIRPα, such as between human CD47 and human SIRPα.

[0014] The present invention also provides bispecific antibodies that recognize CD47 and a second target. The present invention allows identification, production and purification of bispecific antibodies that are indistinguishable from standard antibodies in sequence and in which one of the binding sites is specific for CD47 and the second binding site is specific for another target, such as a tumor-associated antigen (TAA). In some embodiments, TAA is an antigen expressed on the cell surface of a cancer cell. In some embodiments, the cancer cell is selected from lung cancer cells, bronchial cancer cells, prostate cancer cells, breast cancer cells, colorectal cancer cells, pancreatic cancer cells, ovarian cancer, leukemia cancer cells, lymphoma cancer cells, esophageal cancer cells, liver cancer cells, urinary and / or bladder cancer cells, renal cancer cells, oral cancer cells, pharyngeal cancer cells, uterine cancer cells, and / or melanoma cancer cells.

[0015] The bispecific antibodies of the present invention and fragments thereof that bind to at least CD47 are used to regulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with the functional activity of CD47. The functional activity of CD47 includes, but is not limited to, interaction with SIRPα. When the level of CD47-SIRPα interaction in the presence of the antibody is reduced by at least 95%, such as 96%, 97%, 98%, 99% or 100%, compared to the level of CD47-SIRPα interaction in the absence of binding to the antibodies described herein, the antibody is considered to fully regulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with the CD47-SIRPα interaction. When the level of CD47-SIRPα interaction in the presence of the antibody is reduced by less than 95%, such as 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90%, the antibody is considered to partially regulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with the CD47-SIRPα interaction.

[0016] In some embodiments, the bispecific antibody exhibits a "balanced" affinity for each of the two targets. In other embodiments, the bispecific antibody exhibits an "unbalanced" affinity for each of the two targets. For example, in an anti-CD47 / MSLN bispecific antibody, the affinity of the anti-MSLN arm increases. For example, in an anti-CD47 / MSLN bispecific antibody, the affinity of the anti-CD47 arm decreases. For example, in an anti-CD47 / MSLN bispecific antibody, the affinity of the anti-MSLN arm increases and the affinity of the anti-CD47 arm decreases. These unbalanced affinity bispecific antibodies can, for example, be used to improve the selectivity of a target cell or a group of target cells.

[0017] In some embodiments, the affinity of the anti-MSLN arm increases at least 100-fold after affinity maturation. In some embodiments, the affinity of the anti-CD47 arm decreases at least 2-fold after affinity dematuration. For example, in some embodiments, the anti-CD47 arm exhibits an affinity for CD47 of about 2-fold to less than 100-fold after affinity dematuration.

[0018] In some embodiments, the first arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) amino acid sequence of SEQ ID NO: 225, a variable heavy chain complementarity determining region 2 (CDRH2) amino acid sequence of SEQ ID NO: 226, a variable heavy chain complementarity determining region 3 (CDRH3) amino acid sequence of SEQ ID NO: 227, a variable light chain complementarity determining region 1 (CDRL1) amino acid sequence selected from SEQ ID NOs: 228-241 and 262-272, a variable light chain complementarity determining region 2 (CDRL2) amino acid sequence selected from SEQ ID NOs: 242-245 and 273-280, and a variable light chain complementarity determining region 3 (CDRL3) amino acid sequence selected from SEQ ID NOs: 246-261 and 281.

[0019] In some embodiments, the first arm amino acid sequence includes a variable heavy chain amino acid sequence of SEQ ID NO: 114 and a variable light chain amino acid sequence selected from the group consisting of SEQ ID NO: 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206.

[0020] In some embodiments, the first arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:240, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:242, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:254.

[0021] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:168.

[0022] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a variable light chain comprising the amino acid sequence of SEQ ID NO:56.

[0023] In some embodiments, the second arm amino acid sequence includes a heavy chain amino acid sequence of SEQ ID NO: 2 and a light chain amino acid sequence selected from SEQ ID NO: 98, 100, 102, 104, 106, 108 and 110.

[0024] In some embodiments, the second arm amino acid sequence includes a variable heavy chain amino acid sequence of SEQ ID NO: 114 and a variable light chain amino acid sequence selected from SEQ ID NO: 212, 214, 216, 218, 220, 222 and 224.

[0025] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) amino acid sequence selected from SEQ ID NOs:282-287, a variable light chain complementarity determining region 2 (CDRL2) amino acid sequence selected from SEQ ID NOs:288-293, and a variable light chain complementarity determining region 3 (CDRL3) amino acid sequence selected from SEQ ID NOs:294-300.

[0026] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:282, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:288, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:294.

[0027] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:283, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:289, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:295.

[0028] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:284, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:290, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:296.

[0029] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:285, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:291, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:297.

[0030] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:286, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:292, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:298.

[0031] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:287, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:293, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:299.

[0032] In some embodiments, the second arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:282, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:288, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:300.

[0033] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising an amino acid sequence selected from SEQ ID NO: 212, 214, 216, 218, 220, 222 and 224.

[0034] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:212.

[0035] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:214.

[0036] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:216.

[0037] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:218.

[0038] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:220.

[0039] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:222.

[0040] In some embodiments, the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:224.

[0041] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising an amino acid sequence selected from SEQ ID NO: 98, 100, 102, 104, 106, 108 and 110.

[0042] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:98.

[0043] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:100.

[0044] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:102.

[0045] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:104.

[0046] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:106.

[0047] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:108.

[0048] In some embodiments, the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:110.

[0049] In some embodiments, the first arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO: 226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO: 227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO: 240, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO: 242, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a variable light chain complementarity determining region 1 (CDRL1) amino acid sequence selected from SEQ ID NOs: 282-287, a variable light chain complementarity determining region 2 (CDRL2) amino acid sequence selected from SEQ ID NOs: 288-293, and a variable light chain complementarity determining region 3 (CDRL3) selected from SEQ ID NOs: The variable light chain complementarity determining region 3 (CDRL3) amino acid sequence of NO:294-300.

[0050] In some embodiments, the first arm amino acid sequence includes a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO: 226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO: 227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO: 240, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO: 242, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO: 282, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO: 288, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO: 294.

[0051] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 283, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 289, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 295.

[0052] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 284, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 290, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 296.

[0053] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 285, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 291, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 297.

[0054] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 286, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 292, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 298.

[0055] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 287, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 293, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 299.

[0056] In some embodiments, the first arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 240, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 254, and the second arm amino acid sequence includes a CDRH1 comprising the amino acid sequence of SEQ ID NO: 225, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 226, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 227, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 282, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 288, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 300.

[0057] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising an amino acid sequence selected from SEQ ID NOs: 212, 214, 216, 218, 220, 222, and 224.

[0058] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 212.

[0059] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 214.

[0060] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 216.

[0061] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 218.

[0062] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 220.

[0063] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 222.

[0064] In some embodiments, the first arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 168, and the second arm amino acid sequence includes a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 224.

[0065] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising an amino acid sequence selected from SEQ ID NOs:98, 100, 102, 104, 106, 108 and 110.

[0066] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:98.

[0067] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:100.

[0068] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:102.

[0069] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:104.

[0070] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:106.

[0071] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:108.

[0072] In some embodiments, the first arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:168, and the second arm amino acid sequence includes a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:110.

[0073] In some embodiments, the bispecific antibody comprises two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different.

[0074] In some embodiments, at least a portion of the first light chain is of κ type and at least a portion of the second light chain is of λ type. In some embodiments, the first light chain includes at least one κ constant region. In some embodiments, the first light chain further includes a κ variable region. In some embodiments, the first light chain further includes a λ variable region. In some embodiments, the second light chain includes at least one λ constant region. In some embodiments, the second light chain further includes a λ variable region. In some embodiments, the second light chain further includes a κ variable region. In some embodiments, the first light chain includes a κ constant region and a κ variable region, and wherein the second light chain includes a λ constant region and a λ variable region.

[0075] In some embodiments, the constant and variable framework region sequences are human.

[0076] The bispecific antibodies of the invention are produced using any method known in the art, such as, but not limited to, the use of cross-linked fragments, cell hybridomas, and / or any of a variety of recombinant formats, such as, but not limited to, linked antibody fragments, forced heterodimers, and or single domain-based recombinant formats. Examples of bispecific formats include, but are not limited to: bispecific IgG based on Fab arm exchange (Gramer et al., 2013 MAbs. 5(6)); CrossMab format (Klein C et al., 2012 MAbs 4(6)); various formats based on forced heterodimerization methods such as SEED technology (Davis JH et al., 2010 Protein Eng Des Sel. 23(4):195-202), electrostatic manipulation (Gunasekaran K et al., J Biol Chem. 2010 285(25):19637-46.) or knob-into-hole (Ridgway JB et al., Protein Eng. 1996 9(7):617-21.) or other sets of mutations that prevent homodimer formation (Von Kreudenstein TS et al., 2013 MAbs. 5(5):646-54.); fragment-based bispecific formats such as tandem scFv (such as BiTEs) (Wolf E et al., 2005 Drug Discov. Today 10(18):1237-44.); bispecific tetravalent antibodies (Pörtner LM et al., 2012 Cancer Immunol Immunother. 61(10):1869-75.); dual affinity retargeting molecules (Moore PA et al., 2011 Blood. 117(17):4542-51), diabodies (Kontermann RE et al., Nat Biotechnol. 1997 15(7):629-31).

[0077] In some embodiments, the bispecific antibody has a single heavy chain polypeptide with different specificities at each binding site and includes two copies and a first light chain and a second light chain, wherein the first and second light chains are different. In some embodiments, at least a portion of the first light chain is κ type and at least a portion of the second light chain is λ type. In some embodiments, the first light chain includes at least one κ constant region. In some embodiments, the first light chain further includes a κ variable region. In some embodiments, the first light chain further includes a λ variable region. In some embodiments, the second light chain includes at least one λ constant region. In some embodiments, the second light chain further includes a λ variable region. In some embodiments, the second light chain further includes a κ variable region. In some embodiments, the first light chain includes a κ constant region and a κ variable region, and the second light chain includes a λ constant region and a λ variable region. In some embodiments, the constant and variable framework region sequences are human.

[0078] The present invention provides monoclonal antibodies that bind to MSLN. These antibodies are collectively referred to herein as anti-MSLN monoclonal antibodies or anti-MSLN mAbs. Preferably, the monoclonal antibodies are specific for at least human MSLN. In some embodiments, the monoclonal antibodies that recognize human MSLN are also cross-reactive with at least one other non-human MSLN protein (such as, by way of non-limiting example, non-human primate MSLN, e.g., cynomolgus MSLN, and / or rodent MSLN).

[0079] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) amino acid sequence selected from SEQ ID NOs:282-287, a variable light chain complementarity determining region 2 (CDRL2) amino acid sequence selected from SEQ ID NOs:288-293, and a variable light chain complementarity determining region 3 (CDRL3) amino acid sequence selected from SEQ ID NOs:294-300.

[0080] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:282, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:288, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:294.

[0081] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:283, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:289, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:295.

[0082] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:284, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:290, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:296.

[0083] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:285, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:291, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:297.

[0084] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:286, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:292, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:298.

[0085] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:287, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:293, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:299.

[0086] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:225, a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:226, a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:227, a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:282, a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:288, and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:300.

[0087] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a variable light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 212, 214, 216, 218, 220, 222, and 224.

[0088] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:212.

[0089] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:214.

[0090] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:216.

[0091] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:218.

[0092] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:220.

[0093] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:222.

[0094] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:114 and a variable light chain comprising the amino acid sequence of SEQ ID NO:224.

[0095] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:98, 100, 102, 104, 106, 108, and 110.

[0096] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:98.

[0097] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:100.

[0098] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:102.

[0099] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:104.

[0100] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:106.

[0101] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:108.

[0102] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:2 and a light chain comprising the amino acid sequence of SEQ ID NO:110.

[0103] In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the anti-MSLN monoclonal antibody comprises a variable light chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the variable light chain portion of the amino acid sequence selected from SEQ ID NO: 98, 100, 102, 104, 106, 108 and 110. In some embodiments, the anti-MSLN monoclonal antibody comprises a variable heavy chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 114, and a variable light chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the variable light chain amino acid sequence selected from SEQ ID NO: 212, 214, 216, 218, 220, 222 and 224.

[0104] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the anti-MSLN monoclonal antibody comprises a light chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 98, 100, 102, 104, 106, 108 and 110. In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 114, and a light chain amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence selected from SEQ ID NO: 98, 100, 102, 104, 106, 108 and 110.

[0105] In some embodiments, the anti-MSLN monoclonal antibody comprises a heavy chain amino acid sequence of SEQ ID NO:2 and a light chain amino acid sequence selected from SEQ ID NO:98, 100, 102, 104, 106, 108 and 110.

[0106] The present invention also provides monovalent antibodies that bind to MSLN. These antibodies are collectively referred to herein as anti-MSLN monovalent antibodies or anti-MSLN monovalent (monov) mAbs. The monovalent antibodies of the present invention include an arm that specifically recognizes MSLN and a second arm referred to herein as a dummy arm. The dummy arm includes an amino acid sequence that does not bind to human proteins or does not otherwise cross-react with human proteins. In some embodiments, the dummy arm includes an amino acid sequence that does not bind to human proteins found in whole blood or does not otherwise cross-react with them. In some embodiments, the dummy arm includes an amino acid sequence that does not bind to human proteins found in solid tissues or does not otherwise cross-react with them. Preferably, the monovalent antibody is specific for at least human MSLN. In some embodiments, the monovalent antibody that recognizes human MSLN is also cross-reactive for at least one other non-human MSLN protein (such as, but not limited to, non-human primate MSLN, for example, cynomolgus monkey MSLN and / or rodent MSLN).

[0107] The present invention also provides bispecific antibodies that recognize MSLN and a second target.

[0108] The bispecific antibodies of the present invention that recognize MSLN and a second target are produced using any method known in the art, such as, but not limited to, the use of cross-linked fragments, cell hybridomas, and / or any of a variety of recombinant formats, such as, but not limited to, linked antibody fragments, forced heterodimers, and or single domain-based recombinant formats. The present invention allows the identification, production, and purification of bispecific antibodies that are indistinguishable in sequence from standard antibodies and in which one of the binding sites is specific for MSLN and the second binding site is specific for another target, such as a tumor-associated antigen (TAA). The unmodified nature of the antibodies of the present invention lends them to advantageous preparation and biochemical characteristics similar to those of standard monoclonal antibodies.

[0109] In some embodiments, the bispecific antibody has a different specificity at each binding site and comprises two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different.

[0110] In some embodiments, at least a portion of the first light chain is of κ type and at least a portion of the second light chain is of λ type. In some embodiments, the first light chain includes at least one κ constant region. In some embodiments, the first light chain further includes a κ variable region. In some embodiments, the first light chain further includes a λ variable region. In some embodiments, the second light chain includes at least one λ constant region. In some embodiments, the second light chain further includes a λ variable region. In some embodiments, the second light chain further includes a κ variable region. In some embodiments, the first light chain includes a κ constant region and a κ variable region, and the second light chain includes a λ constant region and a λ variable region. In some embodiments, the constant and variable framework region sequences are human.

[0111] The monoclonal, monovalent and / or bispecific antibodies of the present invention can be used for therapeutic intervention or as research or diagnostic reagents. For example, the monoclonal, monovalent and / or bispecific antibodies of the present invention can be used in a method for treating, preventing and / or delaying the progression of pathologies associated with abnormal CD47 and / or abnormal CD47-SIRPα expression and / or activity or alleviating symptoms associated with such pathologies by administering the antibodies of the present invention to a subject in need of such treatment or prevention. The subject to be treated is, for example, a human. The monoclonal, monovalent and / or bispecific antibodies are administered in an amount sufficient to treat, prevent, delay progression or alleviate symptoms associated with the pathology.

[0112] In some embodiments, the monoclonal, monovalent and / or bispecific antibodies of the invention can be used in methods for treating, preventing and / or delaying the progression of cancer or other neoplastic diseases or alleviating the symptoms of cancer or other neoplastic diseases by administering the antibodies of the invention to a subject in which treatment or prevention is desired. For example, the monoclonal, monovalent and / or bispecific antibodies described herein can be used to treat hematological malignancies and / or solid tumors. For example, the monoclonal, monovalent and / or bispecific antibodies described herein can be used to treat CD47 + Tumor, mesothelin +Tumors and combinations thereof. By way of non-limiting example, the monoclonal, monovalent and / or bispecific antibodies described herein can be used to treat non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, mesothelioma, colorectal cancer, bile duct cancer, pancreatic cancer (including pancreatic adenocarcinoma), lung cancer (including lung adenocarcinoma), leiomyoma, leiomyosarcoma, kidney cancer, glioma, glioblastoma, endometrial cancer, esophageal cancer, biliary gastric cancer and prostate cancer. Solid tumors include, for example, breast tumors, ovarian tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma tumors, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors and kidney tumors.

[0113] In some embodiments, the monoclonal, monovalent and / or bispecific antibodies described herein are used in combination with one or more additional agents or combinations of additional agents. Suitable additional agents include drug therapies and / or surgical therapies currently used for the intended application such as, for example, cancer, inflammation, and / or autoimmune diseases. In some embodiments, the monoclonal, monovalent and / or bispecific antibodies can be used in combination with rituximab.

[0114] In some embodiments, monoclonal, monovalent and / or bispecific antibodies and other agents are formulated into a single therapeutic composition, and monoclonal, monovalent and / or bispecific antibodies and other agents are administered simultaneously. Alternatively, monoclonal, monovalent and / or bispecific antibodies and other agents are separated from each other, for example, each is formulated into a separate therapeutic composition, and monoclonal, monovalent and / or bispecific antibodies and other agents are administered simultaneously, or monoclonal, monovalent and / or bispecific antibodies and other agents are administered at different times during the treatment regimen. For example, monoclonal, monovalent and / or bispecific antibodies are administered before administering other agents, monoclonal, monovalent and / or bispecific antibodies are administered after administering other agents, or monoclonal, monovalent and / or bispecific antibodies and other agents are administered in an alternating manner. As described herein, monoclonal, monovalent and / or bispecific antibodies and other agents are administered in a single dose or in multiple doses.

[0115] Pathologies that may be treated and / or prevented using the antibodies of the invention include, for example, cancer or any other disease or disorder associated with aberrant CD47 expression and / or activity.

[0116] The pharmaceutical compositions according to the invention may comprise the antibody of the invention and a carrier. These pharmaceutical compositions may be included in a kit, such as, for example, a diagnostic kit. BRIEF DESCRIPTION OF THE DRAWINGS

[0118] Figure 1 a-1g are a series of graphs depicting binding experiments of CD47 / MSLN κλ bodies with the corresponding MSLN mAbs. Figure 1 In a-1g, biAb O25 ( Figure 1 a), biAb O30 ( Figure 1 b), biAb O32 ( Figure 1 c), biAb O35 ( Figure 1 d) biAbO37 ( Figure 1 e), biAb O38 ( Figure 1 f) and biAb O41 ( Figure 1 g) Binding to human MSLN-transfected CHO cells (CHO-huMSLN, left), cynomolgus MSLN-transfected CHO cells (CHO-cyMSLN, middle) and untransfected CHO cells (right) was assessed by flow cytometry as a dose-response and expressed as mean fluorescence intensity. Comparison between the binding profiles of CHO-huMSLN and CHO-cyMSLN showed that the CD47 / MSLN κλ body and MSLN mAb of the invention cross-reacted with cynomolgus MSLN and that they bound to MSLN from both species with comparable affinity.

[0119] Figures 2A-2F is a series of graphs depicting antibody-dependent cellular phagocytosis (ADCP) induced by CD47 / MSLN κλ bodies compared to benchmark mAbs targeting CD47 or mesothelin. Figures 2A-2F In the Figure, the level of induced ADCP is shown as the percentage of phagocytosis induced by increasing concentrations of bispecific antibodies (biAbs), CD47 mAb B6H12 (with a human IgG1 portion), MSLN mAb amatuximab, and corresponding anti-MSLN monovalent antibodies (i.e., antibodies with an anti-MSLN antibody arm and a non-binding antibody arm), as assessed by flow cytometry. Human macrophages differentiated from peripheral blood mononuclear cells and two target cell lines NCI-N87 ( Figures 2A-2C ) and HPAC( Figure 2E and 2F ) for phagocytosis. The cell surface expression levels of CD47 and mesothelin of NCI-N87 cells were 43,000 and 27,000, respectively. The cell surface expression levels of CD47 and mesothelin of HPAC cells were 105,000 and 13,000, respectively.

[0120] Figures 3A-3Jis a series of graphs depicting ADCP activity induced by CD47 / MSLNκλ bodies compared to matched anti-MSLN mAbs and monovalent antibodies. Human macrophages were cultured against two target cell lines, NCI-N87 ( Figures 3A-3E ) and Caov-3( Figure 3F-3J ) were imaged and quantified using the CellInsight CX5 high-content screening platform. Figures 3A-3J The phagocytic index, which corresponds to the average number of target cells taken up by 100 macrophages, is depicted. The levels of cell surface expression of CD47 and mesothelin for NCI-N87 cells were 43,000 and 27,000, respectively. The levels of cell surface expression of CD47 and mesothelin for Caov-3 cells were 220,000 and 38,000, respectively.

[0121] Figure 4 a-4c are a series of graphs depicting dose-response ADCC experiments using CD47 / MSLN κλ bodies compared to the benchmark MSLN monoclonal antibody amasimab. Whole human PBMCs and three Cr51-loaded MSLN-positive target cell lines NCI-N87 ( Figure 4 a), NCI-H226 ( Figure 4 b) and HepG2-MSLN ( Figure 4 c) ADCC assay was performed. Target cell killing was assessed using a Cr51-releasing cell-based assay. The percentage of ADCC was determined as specific Cr51 release, which was calculated using the following formula: %ADCC = ((sample cpm - non-specific lysis control cpm) / (total lysis control cpm - negative control cpm)) x 100%. CD47 / MSLN κλ body induced dose-dependent killing of target cells, which was significantly higher than that with the benchmark MSLN mAb.

[0122] Figure 5A and 5B The antitumor activity of the five CD47 / MSLN κλ antibodies against the corresponding CD47 monovalent antibodies and the benchmark monoclonal antibodies, CD47 Mab B6H12 (on a human IgG1 background) and MSLN mAb amatuximab are shown. Figure 5A and 5B In this study, HepG2-MSLN cells were implanted subcutaneously into NOD / SCID mice. Antibody treatment was started 15 days later. Figure 5A) Tumor growth progression. Tumor growth was measured three times per week and is shown as mean tumor volume + / - SEM for each group (n=7). Statistical significance was determined at endpoint (D55) using one-way ANOVA followed by multiple comparison test (Tukey's multiple comparisons), p-values: *p<0.05, **p<0.01; ns, not significant. ( Figure 5B ) Tumor growth inhibition (TGI). The percentage of TGI compared to isotype control was determined based on tumor volume at endpoint using the following formula: %TGI = {1- [(Tt–T0) / (Vt-V0)]} x 100; where Tt = median tumor volume of treatment at time t; T0 = median tumor volume of treatment at time 0; Vt = median tumor volume of control at time t, and V0 = median tumor volume of control at time 0. BiAb treatment significantly reduced tumor growth compared to control. In addition, 4 of the 5 biAbs tested proved to be more effective than the MSLN benchmark mAb amatuximab.

[0123] Fig. 6A and 6B The antitumor activity of biAbO38 was shown against two MSLN-expressing ovarian cancer cell lines. Fig. 6A and 6B In the experiment, tumor OVCAR3 and CaOV3 cells were implanted subcutaneously into NOD / SCID mice, respectively. Antibody treatment was started 1 day later. Fig. 6A Shows the progression of OVCAR3 tumor growth. Figure 6B CaOV3 tumor growth progression is shown. Tumor growth was measured three times per week and is shown as mean tumor volume + / - SEM for each group (n=6 or 7). biAbO38 treatment prevented tumor growth (compared to control IgG).

[0124] Details

[0125] CD47 or Integrin-associated protein (IAP) is a ubiquitous 50 kDa transmembrane glycoprotein with multiple functions in cell-cell communication. It interacts with a variety of ligands such as integrins and / or SIRPα. In the context of the innate immune system, CD47 functions as a self-marker, transmitting an inhibitory "don't kill me" signal by binding to SIRPα expressed by myeloid cells such as macrophages, neutrophils and dendritic cells. Therefore, the role of CD47, which is widely expressed in physiological situations, is to protect healthy cells from elimination by the innate immune system (Oldenborg PA, et al., CD47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and ComplementReceptor–MediatedPhagocytosis, J Exp Med. 2001 Apr 2;193(7):855-62; MattiasOlsson, Role of the CD47 / SIRPαinteraction in regulation ofmacrophagephagocytosis, Department of Integrative Medical Biology, Sectionfor Histology and Cell Biology, Umeå University, Umeå, Sweden, Thesis; Oldenborg PA., Role ofCD47 in erythroid cells and in autoimmunity, LeukLymphoma. 2004 Jul;45(7):1319-27; Oldenborg PA, et al., Role of CD47 as aMarker of Self onRed Blood Cells., Science. 2000 Jun 16;288(5473):2051-4;Brown EJ, Frazier WA., integrin-associated protein (CD47) and its ligands., Trends Cell Biol. 2001Mar;11(3):130-5).

[0126] Tumor cells hijack this immunosuppressive mechanism by overexpressing CD47, which effectively helps them escape immune surveillance and be killed by innate immune cells. (Majeti R, Ch et al., CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells, Cell. 2009 Jul 23; 138(2): 286-99; S. Jaiswal et al., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis., Cell. 2009 Jul 23; 138(2): 271-85)). CD47 expression is upregulated in most human cancers (e.g., NHL, AML, breast cancer, colon cancer, glioblastoma, glioma, ovarian cancer, bladder cancer, and prostate cancer) and elevated CD47 expression levels are significantly associated with aggressive disease and poor survival. (MajetiR, et al., Cell. 2009 Jul 23;138(2):286-99; S. Jaiswal et al., Cell. 2009 Jul 23;138(2):271-85; Willingham SB, et al., The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors, Proc Natl AcadSci US A. 2012 Apr 24;109(17):6662-7; Chao MP, et al., Therapeutic antibodytargeting of CD47 eliminates human acute lymphoblastic leukemia., Cancer Res. 2011 Feb 15;71(4):1374-84).

[0127] The ubiquitous expression of CD47 in healthy tissues raises questions about therapeutic safety and efficacy: First, targeting CD47 with neutralizing monoclonal antibodies (Mabs) can affect healthy tissues, leading to severe toxicity as shown in preclinical studies with mice and cynomolgus monkeys (Willingham SB, et al., Proc Natl Acad Sci US A. 2012 Apr 24;109(17):6662-7; Weiskopf K, et al., Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies, Science. 2013 Jul 5;341(6141):88-91). Second, even if severe toxicity can be avoided or mitigated by using alternative forms (Weiskopf K, et al., Science. 2013 Jul 5;341(6141):88-91), the ubiquitous expression of CD47 still causes rapid elimination of CD47 binding molecules via target-mediated drug distribution, resulting in poor pharmacokinetics and reduced efficacy.

[0128] Mesothelin (MSLN) is a 40 kDa glycosylphosphatidylinositol (GPI)-linked cell surface glycoprotein that is generated by hydrolysis of a 71 kDa precursor protein. In normal tissues, mesothelin is expressed - at relatively low levels - only in mesothelial cells lining serous membranes such as the pleura, peritoneum, and pericardium. The normal physiological function of mesothelin remains unclear, but it appears to be essential, as mesothelin-deficient mice grow and reproduce normally and exhibit no overt abnormalities.

[0129] Compared with normal tissue, mesothelin is highly expressed in several types of solid tumors such as malignant mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, as well as endometrial cancer, biliary gastric cancer and prostate cancer. Tumor mesothelin expression has been often associated with increased tumor aggressiveness and poor clinical outcomes. The binding of mesothelin to the ovarian cancer antigen MUC16 (CA-125) has been shown to mediate cell-cell adhesion, which may contribute to metastatic spread. In addition, mesothelin-mediated intracellular signaling has been reported to promote tumor cell proliferation, as well as resistance to chemotherapy and anoikis (programmed cell death caused by the loss of normal cell-matrix interactions).

[0130] Similar to most other GPI-anchored proteins, mesothelin is shed from the membrane, and soluble mesothelin has been reported in the serum of tumor patients. Therefore, soluble mesothelin is a useful biomarker for diagnosing mesothelin-positive tumors, but also for monitoring disease progression and response to treatment. Soluble mesothelin is also considered a negative prognostic biomarker for patients with ovarian, lung or pancreatic adenocarcinoma, and triple-negative breast cancer. Last but not least, serum mesothelin levels are predictive biomarkers in mesothelioma, as they have been found to be positively correlated with therapeutic response to mesothelin-targeted therapies.

[0131] Most tumor-associated antigens used to therapeutically target solid tumors are also expressed in the necessary normal tissues. In contrast, the expression of mesothelin is usually low and limited to mesothelial cells (which seems to be necessary). On the other hand, the cell surface expression of mesothelin is high in many solid tumors, which makes mesothelin a particularly attractive target for therapeutic intervention. Therefore, many mesothelin-directed therapies using monoclonal antibodies, recombinant immunotoxins, antibody-drug conjugates, cancer vaccines and chimeric antigen receptor T cells are currently under development (including clinical evaluation for MPM and pancreatic adenocarcinoma in late-stage trials).

[0132] The present invention also provides a bispecific antibody that recognizes CD47 and mesothelin.

[0133] The bispecific antibodies of the present invention allow two antibody arms to bind to two antigens on the cell surface at the same time (called co-engagement), which results in an additive or synergistic increase in affinity due to the antibody-antigen affinity mechanism. As a result, co-engagement confers high selectivity to cells expressing two antigens compared to cells expressing only a single antigen. In addition, the affinity of the two arms of the bispecific antibody to their corresponding targets can be set in a manner such that binding to the target cell is mainly driven by one of the antibody arms. In some embodiments, the bispecific antibody includes a first arm that binds to CD47 and a second arm that binds to mesothelin, wherein the second arm binds to mesothelin with high affinity, and the first arm binds to CD47 with low affinity, i.e., mesothelin is sufficient to inhibit the affinity of CD47 / SIRPα when co-engaged. This design allows the bispecific antibodies of the present invention to preferentially inhibit CD47 in cancer compared to normal cells. In the examples provided herein, bispecific antibodies (referred to as CD47xMSLN bispecifics) having a first arm that binds CD47 with low affinity and a second arm that binds MSLN with high affinity allow preferential inhibition of CD47 in cancer over normal cells. In addition to the two antigen binding arms, the CD47xMSLN bispecific antibodies require a functional Fc portion to recruit macrophages and / or other immune effector cells. Fully human bispecific IgG formats (such as the κλ body formats described herein) are very suitable for generating dual-targeted CD47 x MSLN bispecific antibodies. The ability of dual-targeted bispecific antibodies to co-link CD47 and MSLN results in effective and selective cancer cell killing mediated by the CD47xMSLN bispecific antibodies, as demonstrated in ADCC and ADCP experiments provided herein.

[0134] Exemplary bispecific antibodies of the invention wherein at least one binding site is specific for CD47 and the second binding site is specific for mesothelin include, for example, bispecific antibodies wherein the first arm comprises a 5A3 antibody, a 5A3M4 antibody, a 5A3M3 antibody, a 5A3M5 antibody, a KE8 antibody, a KE8-P6H5 antibody (also referred to herein as KE8H5), a KE8-P3B2 antibody (also referred to herein as KE8B2), a KE8-P2A2 antibody (also referred to herein as KE8 E8A25), KE8F2 antibody, KE8G2 antibody, KE84G9 antibody, KE81G9 antibody, KE81A3 antibody, KE8E8 antibody, KE8G6 antibody, KE8H3 antibody, KE8C7 antibody, KE8A4 antibody, KE8A8 antibody, KE8G11 antibody, KE8B7 antibody, KE8F1 antibody, KE8C4 antibody, KE8A3 antibody, KE86G9 antibody, KE8H6 antibody, KA3 antibody, KA3-P5G 2 antibody (also referred to herein as KA3G2), KA3-P1A3 antibody (also referred to herein as KA3A3), KA3-P5C5 antibody (also referred to herein as KA3C5), KA3H8 antibody, KA3B2 antibody, KA3A2 antibody, KA3D3 antibody, KA3H3 antibody, KC4 antibody, KC4-P1G11KC4-P4C11 antibody, KC4-P6B1KC4-P4F4 antibody, and KC4-P2E2 antibody (also referred to herein as KC4 E2), KC4 antibody, KC4F4 antibody, KC4A1 antibody, KC4C11 antibody, KC4E10 antibody, KC4B1 antibody, KC4C3 antibody, KC4A4 antibody, KC4G11 antibody or KC4G9 antibody and immunologically active and / or antigen-binding fragments thereof, and wherein the second arm comprises O25 antibody, O30 antibody, O32 antibody, O35 antibody, O37 antibody, O38 antibody or O41 antibody and immunologically active and / or antigen-binding fragments thereof.

[0135] In some embodiments, an exemplary bispecific antibody of the invention comprising at least a first arm that binds CD47 comprises a combination of heavy and light chain complementarity determining regions (CDRs) selected from the CDR sequences shown in Tables 1, 2, and 3, wherein the CDRs shown in Tables 1, 2, and 3 are identified according to IMGT nomenclature.

[0136] In some embodiments, an exemplary bispecific antibody of the invention comprising at least a first arm that binds CD47 comprises a combination of a heavy chain CDR sequence from Table 1 and two sets of light chain CDRs selected from the CDRL1, CDRL2, and CDRL3 sequences shown in Tables 2 and 3.

[0137] In some embodiments, an exemplary bispecific antibody of the invention comprising at least a first arm that binds CD47 comprises a combination of a heavy chain CDR sequence from Table 1 and a first set of light chain CDRs selected from the CDRL1, CDRL2, and CDRL3 sequences shown in Table 2 and a second set of light chain CDRs selected from the CDRL1, CDRL2, and CDRL3 sequences shown in Table 3.

[0138] In some embodiments, an exemplary bispecific antibody of the invention comprises a first arm that binds CD47 and a second arm that binds MSLN, wherein the first arm comprises a combination of heavy chain complementarity determining regions (CDRs) shown in Table 1 and a combination of light chain CDRs selected from the CDR sequences shown in Table 2, and wherein the second arm comprises a combination of heavy chain complementarity determining regions (CDRs) shown in Table 1 and a combination of light chain CDRs selected from the CDR sequences shown in Table 4.

[0139] Table 1: Common Heavy Chain CDRs

[0140]

[0141] Table 2: Anti-CD47 kappa light chain CDRs

[0142]

[0143] Table 3: Anti-CD47 Lambda Light Chain CDRs

[0144]

[0145] Table 4: Anti-CD47 Lambda Light Chain CDRs

[0146]

[0147] Each of the exemplary anti-CD47, anti-MSLN monovalent and bispecific antibodies described herein includes a common heavy chain (HC), one κ chain and one λ chain of anti-CD47 and anti-MSLN antibodies, one κ and one λ light chain (LC) of monovalent and bispecific antibodies, as shown in the amino acids and corresponding nucleic acid sequences listed below. Each of the exemplary anti-CD47, anti-MSLN monovalent and bispecific antibodies described below includes a common variable heavy chain (VH), one κ variable light domain and one λ variable light domain of anti-CD47 and anti-MSLN antibodies, one κ and one λ variable light domain (VL) of monovalent and bispecific antibodies, as shown in the amino acids and corresponding nucleic acid sequences listed below.

[0148] Although the antibody sequences below are provided herein as examples, it will be appreciated that these sequences can be used to generate bispecific antibodies using a variety of art-recognized techniques. Examples of bispecific formats include, but are not limited to: bispecific IgG based on Fab arm exchange (Gramer et al., 2013 MAbs. 5(6)); CrossMab format (Klein C et al., 2012 MAbs 4(6)); various formats based on forced heterodimerization methods such as SEED technology (Davis JH et al., 2010 Protein Eng Des Sel. 23(4):195-202), electrostatic manipulation (Gunasekaran K et al., J Biol Chem. 2010 285(25):19637-46.) or knob-into-hole (Ridgway JB et al., Protein Eng. 1996 9(7):617-21.) or other sets of mutations that prevent homodimer formation (Von Kreudenstein TS et al., 2013 MAbs. 5(5):646-54.); fragment-based bispecific formats such as tandem scFv (such as BiTEs) (Wolf E et al., 2005 Drug Discov. Today 10(18):1237-44.); bispecific tetravalent antibodies (Pörtner LM et al., 2012 Cancer Immunol Immunother. 61(10):1869-75.); dual affinity retargeting molecules (Moore PA et al., 2011 Blood. 117(17):4542-51), diabodies (Kontermann RE et al., Nat Biotechnol. 1997 15(7):629-31).

[0149] Exemplary anti-CD47, anti-MSLN monovalent and bispecific antibodies include a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1.

[0150]

[0151]

[0152] The anti-CD47, anti-MSLN monovalent and bispecific antibodies include a common variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113.

[0153]

[0154]

[0155] Anti-CD47 antibody

[0156] The 5A3 antibody includes a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:4) encoded by the nucleic acid sequence shown in SEQ ID NO:3.

[0157]

[0158]

[0159] The 5A3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 116) encoded by the nucleic acid sequence shown in SEQ ID NO: 115.

[0160]

[0161]

[0162] The 5A3-M4 antibody includes a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:6) encoded by the nucleic acid sequence shown in SEQ ID NO:5.

[0163]

[0164]

[0165] The 5A3-M4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 118) encoded by the nucleic acid sequence shown in SEQ ID NO: 117.

[0166]

[0167]

[0168] The 5A3-M3 antibody includes a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:8) encoded by the nucleic acid sequence shown in SEQ ID NO:7.

[0169]

[0170]

[0171] The 5A3-M3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 120) encoded by the nucleic acid sequence shown in SEQ ID NO: 119.

[0172]

[0173]

[0174] The 5A3-M5 antibody includes a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:10) encoded by the nucleic acid sequence shown in SEQ ID NO:9.

[0175]

[0176]

[0177] The 5A3-M5 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 122) encoded by the nucleic acid sequence shown in SEQ ID NO: 121.

[0178]

[0179]

[0180] The Ke8 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:12) encoded by the nucleic acid sequence shown in SEQ ID NO:11.

[0181]

[0182]

[0183] The Ke8 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 124) encoded by the nucleic acid sequence shown in SEQ ID NO: 123.

[0184]

[0185]

[0186] The Ke8H5 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:14) encoded by the nucleic acid sequence shown in SEQ ID NO:13.

[0187]

[0188]

[0189] The Ke8H5 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 126) encoded by the nucleic acid sequence shown in SEQ ID NO: 125.

[0190]

[0191]

[0192] The Ke8B2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:16) encoded by the nucleic acid sequence shown in SEQ ID NO:15.

[0193]

[0194]

[0195] The Ke8B2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 128) encoded by the nucleic acid sequence shown in SEQ ID NO: 127.

[0196]

[0197]

[0198] The Ke8A2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:18) encoded by the nucleic acid sequence shown in SEQ ID NO:17.

[0199]

[0200]

[0201] The Ke8A2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 130) encoded by the nucleic acid sequence shown in SEQ ID NO: 129.

[0202]

[0203]

[0204] The Ke8E8 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:20) encoded by the nucleic acid sequence shown in SEQ ID NO:19.

[0205]

[0206]

[0207] The Ke8E8 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 132) encoded by the nucleic acid sequence shown in SEQ ID NO: 131.

[0208]

[0209]

[0210] The Ke8H3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:22) encoded by the nucleic acid sequence shown in SEQ ID NO:21.

[0211]

[0212]

[0213] The Ke8H3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 134) encoded by the nucleic acid sequence shown in SEQ ID NO: 133.

[0214]

[0215]

[0216] The Ke8G6 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:24) encoded by the nucleic acid sequence shown in SEQ ID NO:23.

[0217]

[0218]

[0219] The Ke8G6 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 136) encoded by the nucleic acid sequence shown in SEQ ID NO: 135.

[0220]

[0221]

[0222] The Ke8A3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:26) encoded by the nucleic acid sequence shown in SEQ ID NO:25.

[0223]

[0224]

[0225] The Ke8A3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 138) encoded by the nucleic acid sequence shown in SEQ ID NO: 137.

[0226]

[0227]

[0228] The Ke81A3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:28) encoded by the nucleic acid sequence shown in SEQ ID NO:27.

[0229]

[0230]

[0231] The Ke81A3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 140) encoded by the nucleic acid sequence shown in SEQ ID NO: 139.

[0232]

[0233]

[0234] The Ke8A8 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:30) encoded by the nucleic acid sequence shown in SEQ ID NO:29.

[0235]

[0236]

[0237] The Ke8A8 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 142) encoded by the nucleic acid sequence shown in SEQ ID NO: 141.

[0238]

[0239]

[0240] The Ke8C7 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:32) encoded by the nucleic acid sequence shown in SEQ ID NO:31.

[0241]

[0242]

[0243] The Ke8C7 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 144) encoded by the nucleic acid sequence shown in SEQ ID NO: 143.

[0244]

[0245]

[0246] The Ke8G2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:34) encoded by the nucleic acid sequence shown in SEQ ID NO:33.

[0247]

[0248]

[0249] The Ke8G2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 146) encoded by the nucleic acid sequence shown in SEQ ID NO: 145.

[0250]

[0251]

[0252] The Ke81G9 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:36) encoded by the nucleic acid sequence shown in SEQ ID NO:35.

[0253]

[0254]

[0255] The Ke81G9 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 148) encoded by the nucleic acid sequence shown in SEQ ID NO: 147.

[0256]

[0257]

[0258] The Ke8F2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:38) encoded by the nucleic acid sequence shown in SEQ ID NO:37.

[0259]

[0260]

[0261] The Ke8F2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 150) encoded by the nucleic acid sequence shown in SEQ ID NO: 149.

[0262]

[0263]

[0264] The Ke8B7 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:40) encoded by the nucleic acid sequence shown in SEQ ID NO:39.

[0265]

[0266]

[0267] The Ke8B7 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 152) encoded by the nucleic acid sequence shown in SEQ ID NO: 151.

[0268]

[0269]

[0270] The Ke8C4 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:42) encoded by the nucleic acid sequence shown in SEQ ID NO:41.

[0271]

[0272]

[0273] The Ke8C4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 154) encoded by the nucleic acid sequence shown in SEQ ID NO: 153.

[0274]

[0275]

[0276] The Ke8F1 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:44) encoded by the nucleic acid sequence shown in SEQ ID NO:43.

[0277]

[0278]

[0279] The Ke8F1 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 156) encoded by the nucleic acid sequence shown in SEQ ID NO: 155.

[0280]

[0281]

[0282] The Ke8G11 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:46) encoded by the nucleic acid sequence shown in SEQ ID NO:45.

[0283]

[0284]

[0285] The Ke8G11 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 158) encoded by the nucleic acid sequence shown in SEQ ID NO: 157.

[0286]

[0287]

[0288] The Ke8H6 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:48) encoded by the nucleic acid sequence shown in SEQ ID NO:47.

[0289]

[0290]

[0291] The Ke8H6 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 160) encoded by the nucleic acid sequence shown in SEQ ID NO: 159.

[0292]

[0293]

[0294] The Ke84G9 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:50) encoded by the nucleic acid sequence shown in SEQ ID NO:49.

[0295]

[0296]

[0297] The Ke84G9 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 162) encoded by the nucleic acid sequence shown in SEQ ID NO: 161.

[0298]

[0299]

[0300] The Ke8A4 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:52) encoded by the nucleic acid sequence shown in SEQ ID NO:51.

[0301]

[0302]

[0303] The Ke8A4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 164) encoded by the nucleic acid sequence shown in SEQ ID NO: 163.

[0304]

[0305]

[0306] The Ke86G9 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:54) encoded by the nucleic acid sequence shown in SEQ ID NO:53.

[0307]

[0308]

[0309] The Ke86G9 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 166) encoded by the nucleic acid sequence shown in SEQ ID NO: 165.

[0310]

[0311]

[0312] The Ka3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55.

[0313]

[0314]

[0315] The Ka3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167.

[0316]

[0317]

[0318] The Ka3A2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:58) encoded by the nucleic acid sequence shown in SEQ ID NO:57.

[0319]

[0320]

[0321] The Ka3A2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 170) encoded by the nucleic acid sequence shown in SEQ ID NO: 169.

[0322]

[0323]

[0324] The Ka3H3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:60) encoded by the nucleic acid sequence shown in SEQ ID NO:59.

[0325]

[0326]

[0327] The Ka3H3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 172) encoded by the nucleic acid sequence shown in SEQ ID NO: 171.

[0328]

[0329]

[0330] The Ka3A3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:62) encoded by the nucleic acid sequence shown in SEQ ID NO:61.

[0331]

[0332]

[0333] The Ka3A3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 174) encoded by the nucleic acid sequence shown in SEQ ID NO: 173.

[0334]

[0335]

[0336] The Ka3H8 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:64) encoded by the nucleic acid sequence shown in SEQ ID NO:63.

[0337]

[0338]

[0339] The Ka3H8 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 176) encoded by the nucleic acid sequence shown in SEQ ID NO: 175.

[0340]

[0341]

[0342] The Ka3B2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:66) encoded by the nucleic acid sequence shown in SEQ ID NO:65.

[0343]

[0344]

[0345] The Ka3B2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 178) encoded by the nucleic acid sequence shown in SEQ ID NO: 177.

[0346]

[0347]

[0348] The Ka3C5 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:68) encoded by the nucleic acid sequence shown in SEQ ID NO:67.

[0349]

[0350]

[0351] The Ka3C5 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 180) encoded by the nucleic acid sequence shown in SEQ ID NO: 179.

[0352]

[0353]

[0354] The Ka3G2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:70) encoded by the nucleic acid sequence shown in SEQ ID NO:69.

[0355]

[0356]

[0357] The Ka3G2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 182) encoded by the nucleic acid sequence shown in SEQ ID NO: 181.

[0358]

[0359]

[0360] The Ka3D3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a kappa light chain (SEQ ID NO:72) encoded by the nucleic acid sequence shown in SEQ ID NO:71.

[0361]

[0362]

[0363] The Ka3D3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a kappa variable light domain (SEQ ID NO: 184) encoded by the nucleic acid sequence shown in SEQ ID NO: 183.

[0364]

[0365]

[0366] The Kc4 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:74) encoded by the nucleic acid sequence shown in SEQ ID NO:73.

[0367]

[0368]

[0369] The Kc4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 186) encoded by the nucleic acid sequence shown in SEQ ID NO: 185.

[0370]

[0371]

[0372] The Kc4G11 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:76) encoded by the nucleic acid sequence shown in SEQ ID NO:75.

[0373]

[0374]

[0375] The Kc4G11 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 188) encoded by the nucleic acid sequence shown in SEQ ID NO: 187.

[0376]

[0377]

[0378] The Kc4C11 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:78) encoded by the nucleic acid sequence shown in SEQ ID NO:77.

[0379]

[0380]

[0381] The Kc4C11 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 190) encoded by the nucleic acid sequence shown in SEQ ID NO: 189.

[0382]

[0383]

[0384] The Kc4A1 antibody includes a universal heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:80) encoded by the nucleic acid sequence shown in SEQ ID NO:79.

[0385]

[0386]

[0387] The Kc4A1 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 192) encoded by the nucleic acid sequence shown in SEQ ID NO: 191.

[0388]

[0389]

[0390] The Kc4A4 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:82) encoded by the nucleic acid sequence shown in SEQ ID NO:81.

[0391]

[0392]

[0393] The Kc4A4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 194) encoded by the nucleic acid sequence shown in SEQ ID NO: 193.

[0394]

[0395]

[0396] The Kc4E10 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:84) encoded by the nucleic acid sequence shown in SEQ ID NO:83.

[0397]

[0398]

[0399] The Kc4E10 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 196) encoded by the nucleic acid sequence shown in SEQ ID NO: 195.

[0400]

[0401]

[0402] The Kc4G9 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:86) encoded by the nucleic acid sequence shown in SEQ ID NO:85.

[0403]

[0404]

[0405] The Kc4G9 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 198) encoded by the nucleic acid sequence shown in SEQ ID NO: 197.

[0406]

[0407]

[0408] The Kc4C3 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:88) encoded by the nucleic acid sequence shown in SEQ ID NO:87.

[0409]

[0410]

[0411] The Kc4C3 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 200) encoded by the nucleic acid sequence shown in SEQ ID NO: 199.

[0412]

[0413]

[0414] The Kc4F4 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:90) encoded by the nucleic acid sequence shown in SEQ ID NO:89.

[0415]

[0416]

[0417] The Kc4F4 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 202) encoded by the nucleic acid sequence shown in SEQ ID NO: 201.

[0418]

[0419]

[0420] The Kc4B1 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:92) encoded by the nucleic acid sequence shown in SEQ ID NO:91.

[0421]

[0422]

[0423] The Kc4B1 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 204) encoded by the nucleic acid sequence shown in SEQ ID NO: 203.

[0424]

[0425]

[0426] The Kc4E2 antibody includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1 and includes a lambda light chain (SEQ ID NO:94) encoded by the nucleic acid sequence shown in SEQ ID NO:93.

[0427]

[0428]

[0429] The Kc4E2 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 96) encoded by the nucleic acid sequence shown in SEQ ID NO: 95.

[0430]

[0431]

[0432] Anti-mesothelin (anti-MSLN) antibodies

[0433] O25 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 98) encoded by the nucleic acid sequence shown in SEQ ID NO: 97. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0434]

[0435]

[0436] The 025 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 212) encoded by the nucleic acid sequence shown in SEQ ID NO: 211.

[0437]

[0438]

[0439] O30 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 100) encoded by the nucleic acid sequence shown in SEQ ID NO: 99. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0440]

[0441]

[0442] The 030 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 214) encoded by the nucleic acid sequence shown in SEQ ID NO: 213.

[0443]

[0444]

[0445] O32 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 102) encoded by the nucleic acid sequence shown in SEQ ID NO: 101. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0446]

[0447]

[0448] The O32 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 216) encoded by the nucleic acid sequence shown in SEQ ID NO: 215.

[0449]

[0450]

[0451] O35 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 104) encoded by the nucleic acid sequence shown in SEQ ID NO: 103. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0452]

[0453]

[0454] The O35 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 218) encoded by the nucleic acid sequence shown in SEQ ID NO: 217.

[0455]

[0456]

[0457] O37 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 106) encoded by the nucleic acid sequence shown in SEQ ID NO: 105. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0458]

[0459]

[0460] The O37 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 220) encoded by the nucleic acid sequence shown in SEQ ID NO: 219.

[0461]

[0462]

[0463] O38 The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 108) encoded by the nucleic acid sequence shown in SEQ ID NO: 107. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0464]

[0465]

[0466] The O38 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 222) encoded by the nucleic acid sequence shown in SEQ ID NO: 221.

[0467]

[0468]

[0469] O41The antibody includes a universal heavy chain (SEQ ID NO: 2) encoded by the nucleic acid sequence shown in SEQ ID NO: 1 and includes a lambda light chain (SEQ ID NO: 110) encoded by the nucleic acid sequence shown in SEQ ID NO: 109. The variable region of the lambda light chain is in bold in the following amino acid sequence.

[0470]

[0471]

[0472] The O41 antibody includes a universal variable heavy domain (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113 and includes a lambda variable light domain (SEQ ID NO: 224) encoded by the nucleic acid sequence shown in SEQ ID NO: 223.

[0473]

[0474]

[0475] Pseudo light chain

[0476] Pseudo light chain 1 (SEQ ID NO:112) is encoded by the nucleic acid sequence shown in SEQ ID NO:111.

[0477]

[0478]

[0479] Pseudo variable light chain domain 1 (SEQ ID NO:206) is encoded by the nucleic acid sequence shown in SEQ ID NO:205.

[0480]

[0481]

[0482] Pseudo light chain 2 (SEQ ID NO:208) is encoded by the nucleic acid sequence shown in SEQ ID NO:207.

[0483]

[0484]

[0485] Pseudo variable light chain domain 2 (SEQ ID NO:210) is encoded by the nucleic acid sequence shown in SEQ ID NO:209.

[0486]

[0487]

[0488] Bispecific Antibodies

[0489] In some embodiments, the bispecific antibody Ka3 x O25 comprises a common heavy chain comprising CDRH1 comprising the amino acid sequence of SEQ ID NO:225, CDRH2 comprising the amino acid sequence of SEQ ID NO:226, CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:240, CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:283, CDRL2 comprising the amino acid sequence of SEQ ID NO:289, and CDRL3 comprising the amino acid sequence of SEQ ID NO:295.

[0490] In some embodiments, the bispecific antibody Ka3 x O25 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 212) encoded by the nucleic acid sequence shown in SEQ ID NO: 211.

[0491] In some embodiments, the bispecific antibody Ka3 x O25 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:98) encoded by the nucleic acid sequence shown in SEQ ID NO:97.

[0492] In some embodiments, the bispecific antibody Ka3x030 comprises a common heavy chain comprising CDRH1 comprising the amino acid sequence of SEQ ID NO:225, CDRH2 comprising the amino acid sequence of SEQ ID NO:226, CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:240, CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:284, CDRL2 comprising the amino acid sequence of SEQ ID NO:290, and CDRL3 comprising the amino acid sequence of SEQ ID NO:296.

[0493] In some embodiments, the bispecific antibody Ka3 x O30 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 214) encoded by the nucleic acid sequence shown in SEQ ID NO: 213.

[0494] In some embodiments, the bispecific antibody Ka3 x O30 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:100) encoded by the nucleic acid sequence shown in SEQ ID NO:99.

[0495] In some embodiments, the bispecific antibody Ka3 x O32 comprises a common heavy chain comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:225, a CDRH2 comprising the amino acid sequence of SEQ ID NO:226, a CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:240, a CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:282, a CDRL2 comprising the amino acid sequence of SEQ ID NO:288, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:294.

[0496] In some embodiments, the bispecific antibody Ka3 x O32 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 216) encoded by the nucleic acid sequence shown in SEQ ID NO: 215.

[0497] In some embodiments, the bispecific antibody Ka3 x O32 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:102) encoded by the nucleic acid sequence shown in SEQ ID NO:101.

[0498] In some embodiments, the bispecific antibody Ka3 x O35 comprises a common heavy chain comprising CDRH1 comprising the amino acid sequence of SEQ ID NO:225, CDRH2 comprising the amino acid sequence of SEQ ID NO:226, CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:240, CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:287, CDRL2 comprising the amino acid sequence of SEQ ID NO:293, and CDRL3 comprising the amino acid sequence of SEQ ID NO:299.

[0499] In some embodiments, the bispecific antibody Ka3 x O35 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 218) encoded by the nucleic acid sequence shown in SEQ ID NO: 217.

[0500] In some embodiments, the bispecific antibody Ka3 x O35 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:104) encoded by the nucleic acid sequence shown in SEQ ID NO:103.

[0501] In some embodiments, the bispecific antibody Ka3 x O37 comprises a common heavy chain comprising CDRH1 comprising the amino acid sequence of SEQ ID NO:225, CDRH2 comprising the amino acid sequence of SEQ ID NO:226, CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:240, CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:285, CDRL2 comprising the amino acid sequence of SEQ ID NO:291, and CDRL3 comprising the amino acid sequence of SEQ ID NO:297.

[0502] In some embodiments, the bispecific antibody Ka3 x O37 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 220) encoded by the nucleic acid sequence shown in SEQ ID NO: 219.

[0503] In some embodiments, the bispecific antibody Ka3 x O37 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:106) encoded by the nucleic acid sequence shown in SEQ ID NO:105.

[0504] In some embodiments, the bispecific antibody Ka3 x O38 comprises a common heavy chain comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:225, a CDRH2 comprising the amino acid sequence of SEQ ID NO:226, a CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:240, a CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:286, a CDRL2 comprising the amino acid sequence of SEQ ID NO:292, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:298.

[0505] In some embodiments, the bispecific antibody Ka3 x O38 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 222) encoded by the nucleic acid sequence shown in SEQ ID NO: 221.

[0506] In some embodiments, the bispecific antibody Ka3 x O38 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:108) encoded by the nucleic acid sequence shown in SEQ ID NO:109.

[0507] In some embodiments, the bispecific antibody Ka3 x O41 comprises a common heavy chain comprising CDRH1 comprising the amino acid sequence of SEQ ID NO:225, CDRH2 comprising the amino acid sequence of SEQ ID NO:226, CDRH3 comprising the amino acid sequence of SEQ ID NO:227, a kappa light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:240, CDRL2 comprising the amino acid sequence of SEQ ID NO:242, and CDRL3 comprising the amino acid sequence of SEQ ID NO:254, and a lambda light chain comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:282, CDRL2 comprising the amino acid sequence of SEQ ID NO:288, and CDRL3 comprising the amino acid sequence of SEQ ID NO:300.

[0508] In some embodiments, the bispecific antibody Ka3 x O41 includes a common heavy chain variable region (SEQ ID NO: 114) encoded by the nucleic acid sequence shown in SEQ ID NO: 113, a kappa light chain variable region (SEQ ID NO: 168) encoded by the nucleic acid sequence shown in SEQ ID NO: 167, and a lambda light chain variable region (SEQ ID NO: 224) encoded by the nucleic acid sequence shown in SEQ ID NO: 223.

[0509] In some embodiments, the bispecific antibody Ka3 x O41 includes a common heavy chain (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQ ID NO:1, a kappa light chain (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQ ID NO:55, and a lambda light chain (SEQ ID NO:112) encoded by the nucleic acid sequence shown in SEQ ID NO:111.

[0510] definition:

[0511] Unless otherwise defined, the scientific and technological terms used in the context of the present invention all have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context requires otherwise, singular terms should also include plural forms and plural terms should also include singular forms. Generally, the nomenclature and techniques used in connection with cell and tissue culture, molecular biology, protein and oligonucleotide or polynucleotide chemistry and hybridization described herein are well-known and those commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis and tissue culture and transformation (e.g., electroporation, lipofection). Enzyme reactions and purification techniques are carried out according to manufacturer specifications, or as commonly performed in the art or as described herein. The aforementioned techniques and procedures are generally carried out according to conventional methods well-known in the art and as described in a plurality of general and more specific references cited and discussed throughout this specification. See, for example, Sambrook et al. Molecular Cloning: A LABORATORY MANUAL (Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)). The terminology used in connection with analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein and the laboratory procedures and techniques thereof are those well known and commonly used in the art. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0512] As used in accordance with the present invention, the following terms, unless otherwise specified, shall be understood to have the following meanings:

[0513] As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. "Specific binding" or "immunoreacts with" or "immunospecific binding" means that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides or with much lower affinity (K). d >10 -6 ) binding. Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, dAb (domain antibodies), single chain, F ab 、F ab' and F (ab')2 Fragments, scFVs, and F ab Expression library.

[0514] The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy" chain (about 50-70 kD). The amino terminus of each chain includes a variable region of about 100-110 or more amino acids that is primarily responsible for antigen recognition. The carboxyl terminal portion of each chain determines the constant region that is primarily responsible for effector function. Typically, antibody molecules obtained from humans refer to any of the classes IgG, IgM, IgA, IgE, and IgD, which differ from one another due to the nature of the heavy chains present in the molecule. Certain classes also have subclasses, such as IgG1, IgG2, and others. In addition, in humans, the light chain can be a kappa chain or a lambda chain.

[0515] The term "monoclonal antibody (MAb)" or "monoclonal antibody composition" as used herein refers to a population of antibody molecules containing only one molecular species of antibody molecules consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibodies are identical in all molecules of the population. MAbs contain an antigen binding site that is capable of immunoreacting with a specific epitope of an antigen characterized by a unique binding affinity therefor.

[0516] The term "antigen binding site" or "binding portion" refers to the portion of an immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly differentiated sequences within the V regions of the heavy and light chains, called "hypervariable regions," are located between more conservative flanking sequences called "framework regions" or "FRs." Thus, the term "FR" refers to amino acid sequences that are naturally located between and adjacent to the hypervariable regions of an immunoglobulin. In an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are placed relative to each other in three-dimensional space to form an antigen binding surface. The antigen binding surface is complementary to the three-dimensional surface of the bound antigen, and the three hypervariable regions of each of the heavy and light chains are called "complementarity determining regions" or "CDRs." The amino acid designations for each domain are consistent with the definitions in Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 196:901-917 (1987), Chothia et al. Nature 342:878-883 (1989).

[0517] As used herein, the term "epitope" includes any protein determinant that can specifically bind to an immunoglobulin, scFv, or T cell receptor. The term "epitope" includes any protein determinant that can specifically bind to an immunoglobulin or a T cell receptor. Epitope determinants are usually composed of molecules (such as amino acids or sugar side chains) grouped in chemically active surfaces and usually have specific three-dimensional structural characteristics and specific charge characteristics. For example, antibodies can be produced against the N-terminal or C-terminal peptide of a polypeptide. When the dissociation constant is ≤ 1 μM; for example ≤ 100 nM, preferably ≤ 10 nM and more preferably ≤ 1 nM, the antibody specifically binds to the antigen.

[0518] As used herein, the terms "immunobinding" and "immunobinding properties" refer to the type of non-covalent interaction that occurs between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength or affinity of the immunobinding interaction can be measured by the dissociation constant (K) of the interaction. d ) in the form of, where the smaller K d=K indicates greater affinity. The immunological binding properties of a selected polypeptide can be quantified using methods known in the art. One such method requires measuring the rates of formation and dissociation of antigen binding sites / antigen complexes, where those rates depend on the concentration of the complex partners, the affinity of the interaction, and geometric parameters that also affect the rates in both directions. Thus, the "on rate constant" (K on ) and the “dissociation rate constant” (K off ) can be determined by calculating the concentration and the actual rates of association and dissociation. (See Nature 361: 186-87 (1993)). off / K on The ratio of allows the removal of all affinity-independent parameters and is equal to the dissociation constant K d (See generally Davies et al. (1990) Annual Rev Biochem 59:439-473). When the equilibrium binding constant (K) is measured by an assay such as a radioligand binding assay or similar assays known to those skilled in the art, d ) is ≤1 μM, e.g., ≤100 nM, preferably ≤10 nM, and more preferably ≤1 nM, the antibodies of the present invention specifically bind to their targets.

[0519] As used herein, the term "isolated polynucleotide" shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which, due to its origin, the "isolated polynucleotide" (1) is not accompanied by all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide to which it is not associated in nature, or (3) does not exist in nature as part of a larger sequence. Polynucleotides according to the present invention include nucleic acid molecules encoding heavy chain immunoglobulin molecules and nucleic acid molecules encoding light chain immunoglobulin molecules as described herein.

[0520] The term "isolated protein" as used herein refers to a protein of cDNA, recombinant RNA, or synthetic origin, or some combination thereof, which, due to its origin or source of derivation, (1) is not associated with proteins found in nature, (2) does not contain other proteins from the same source, e.g., no marine proteins, (3) is expressed by a different type of cell, or (4) does not occur in nature.

[0521] The term "polypeptide" is used herein as a general term to refer to a native protein, fragment, or analog of a polypeptide sequence. Therefore, native protein fragments and analogs are species in the polypeptide genus. Polypeptides according to the present invention include heavy chain immunoglobulin molecules and light chain immunoglobulin molecules as described herein, and antibody molecules formed by a combination comprising heavy chain immunoglobulin molecules and light chain immunoglobulin molecules (such as kappa light chain immunoglobulin molecules, and vice versa) and fragments and analogs thereof.

[0522] The term "naturally occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally altered in the laboratory by man or otherwise is naturally occurring.

[0523] The term "operably linked" as used herein refers to the position of the components described being in a relationship that allows them to function in their intended manner. A control sequence is "operably linked to" a coding sequence in a manner that achieves expression of the coding sequence under conditions compatible with the control sequence.

[0524] The term "control sequence" as used herein refers to a polynucleotide sequence necessary for expression and processing of the coding sequence to which they are connected. The nature of such control sequences depends on the host organism and is different. In prokaryotes, such control sequences generally include promoters, ribosome binding sites, and transcription termination sequences. In eukaryotes, such control sequences generally include promoters and transcription termination sequences. The term "control sequence" is intended to include all components necessary for expression and processing to a minimum extent, and can also include additional components, such as leader sequences and fusion partner sequences, whose presence is advantageous. The term "polynucleotide" as used herein means a polymeric boron of nucleotides of at least 10 bases in length, which are ribonucleotides or deoxynucleotides or modified forms of either type of nucleotides. The term includes DNA in single-stranded and double-stranded forms.

[0525] As used herein, the twenty common amino acids and their abbreviations are in accordance with conventional usage. See Immunology - A Synthesis (Second Edition, ESGolub and DRGren, Eds., Sinauer Associates, Sunderland Mass. (1991)). Stereoisomers (e.g., D-amino acids) of the twenty common amino acids, non-natural amino acids such as α-, α-disubstituted amino acids, N-alkyl amino acids, lactic acid and other uncommon amino acids may also be suitable components of the polypeptides of the present invention. Examples of uncommon amino acids include: 4-hydroxyproline, γ-carboxyglutamic acid, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-methylarginine and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide symbols used herein, according to standard usage and regulations, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl terminal direction.

[0526] When applied to polypeptides, the term "substantial identity" means that two peptide sequences have at least 80% sequence identity, preferably at least 90% sequence identity, more preferably at least 95% sequence identity, and most preferably at least 99% sequence identity when optimally aligned by, for example, the programs GAP or BESTFIT using default gap weights.

[0527] Preferably, residue positions which are not identical differ by conservative amino acid substitutions.

[0528] Conservative amino acid substitutions refer to the interchangeability of residues with similar side chains. For example, a group of amino acids with aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids with aliphatic-hydroxy side chains is serine and threonine; a group of amino acids with amide-containing side chains is asparagine and glutamine; a group of amino acids with aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids with basic side chains is lysine, arginine, and histidine; and a group of amino acids with sulfur-containing side chains is cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine.

[0529] As discussed herein, minor changes in the amino acid sequence of antibodies and immunoglobulin molecules are understood to be encompassed by the present invention, provided that the change in the amino acid sequence remains at least 75%, preferably at least 80%, 90%, 95% and most preferably 99%. In particular, conservative amino acid substitutions are contemplated. Conservative substitutions are those that occur within a family of amino acids related to their side chains. Genetically encoded amino acids are generally divided into the following families: (1) acidic amino acids are aspartic acid, glutamic acid; (2) basic amino acids are lysine, arginine, histidine; (3) non-polar amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar amino acids are glycine, asparagine, glutamine; cysteine, serine, threonine, tyrosine. Hydrophilic amino acids include arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine and threonine. Hydrophobic amino acids include alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine. Other families of amino acids include (i) serine and threonine, which are aliphatic-hydroxyl families; (ii) arginine and glutamine, which are amide-containing families; (iii) alanine, valine, leucine and isoleucine, which are aliphatic families; and (iv) phenylalanine, tryptophan and tyrosine, which are aromatic families. For example, it is reasonable to expect that replacing leucine with isoleucine or valine alone, replacing aspartic acid with glutamic acid alone, replacing threonine with serine alone, or similarly replacing amino acids with structurally related amino acids will not have a significant effect on the binding or properties of the resulting molecule, especially if the substitution does not involve amino acids within framework sites. Whether an amino acid change produces a functional peptide can be easily determined by measuring the specific activity of a polypeptide derivative. The assay is described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be easily prepared by a person of ordinary skill in the art. The preferred amino-terminal and carboxyl-terminal ends of the fragments or analogs occur near the boundaries of the functional domains. The structural and functional domains can be identified by comparing nucleotide and / or amino acid sequence data with public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that appear in other proteins with known structures and / or functions. Methods for identifying protein sequences that fold into known three-dimensional structures are known. Bowie et al. Science 253:164 (1991). Therefore, the above examples demonstrate that those skilled in the art can identify sequence motifs and structural conformations that can be used to define the structural and functional domains of the present invention.

[0530] Preferred amino acid substitutions are those that: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for formed protein complexes, (4) alter binding affinity, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs may include various muteins of sequences other than the naturally occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably, conservative amino acid substitutions) may be made in the naturally occurring sequence (preferably, in portions of the polypeptide outside of the domains that form intermolecular contacts). Conservative amino acid substitutions should not substantially alter the structural characteristics of the parent sequence (e.g., the substituted amino acid should tend not to break up helices formed in the parent sequence, or to disrupt other types of secondary structures that are characteristic of the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, ed., WH Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, NY (1991)); and Thornton et al. Nature 354:105 (1991).

[0531] As used herein, the term "label" or "labeled" refers to the incorporation of a detectable marker, for example, by incorporation of a radiolabeled amino acid or attachment to a polypeptide that can be detected by a labeled avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetric methods). In some cases, labels and markers can also be therapeutic. A variety of methods for labeling polypeptides and glycoproteins are known in the art and can be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H. 14 C. 15 N. 35 S. 90 Y. 99 Tc, 111 In, 125 I. 131I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzyme labels (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotin groups, predetermined polypeptide epitopes recognized by secondary reporter molecules (e.g., leucine zipper paired sequences, binding sites of secondary antibodies, metal binding domains, epitope tags). In some embodiments, the labels are connected by spacer arms of various lengths to reduce potential steric hindrance. As used herein, the term "agent or drug" refers to a compound or composition that can induce a desired therapeutic effect when properly administered to a patient.

[0532] Other chemical terms are used herein according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill, San Francisco (1985)).

[0533] As used herein, "substantially pure" means that the object species is the predominant species present (i.e., on a molar basis, it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition in which the object species comprises at least about 50% (on a molar basis) of all macromolecular species present.

[0534] Typically, a substantially pure composition will contain greater than about 80% of all macromolecular species present in the composition, more preferably greater than about 85%, 90%, 95%, and 99%. Most preferably, the target species is purified to substantial homogeneity (contaminant species cannot be detected in the composition by conventional detection methods), wherein the composition consists essentially of a single macromolecular species.

[0535] The term patient includes both human and veterinary subjects.

[0536] Antibody

[0537] Various procedures known in the art can be used to generate polyclonal or monoclonal antibodies to a given target, such as CD47, a tumor-associated antigen or other target, or to derivatives, fragments, analogs, homologs or orthologs thereof (see, e.g., Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).

[0538] Antibodies are purified by well-known techniques such as affinity chromatography using protein A or protein G, which primarily provides the IgG fraction of immune serum. Subsequently, or alternatively, a specific antigen or epitope thereof that is the target of the immunoglobulin being sought can be immobilized on a column to purify the immunospecific antibodies by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

[0539] In some embodiments, the antibodies of the present invention can be monoclonal antibodies. Monoclonal antibodies are generated, for example, by using the procedures described in the examples provided herein. Antibodies are also generated, for example, by immunizing BALB / c mice with a combination of cell transfectants expressing a high level of a given target on its surface. Hybridomas produced by myeloma / B cell fusions are subsequently screened for the reactivity of the selected target.

[0540] Monoclonal antibodies are prepared, for example, using hybridoma methods such as those described by Kohler and Milstein, Nature, 256:495 (1975). In the hybridoma method, mice, hamsters, or other suitable host animals are typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.

[0541] Immunizing agents will generally include protein antigens, fragments thereof, or fusion proteins thereof. Typically, peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. Lymphocytes are then fused to immortalized cell lines using a suitable fusing agent such as polyethylene glycol to form hybridoma cells (Goding, Monoclonal Antibodies:Principles and Practice , Academic Press, (1986) pp. 59-103). Immortalized cell lines typically transform mammalian cells, especially myeloma cells of rodent, bovine and human origin. Typically, rat or mouse myeloma cell lines are used. Hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridoma will contain hypoxanthine, aminopterin and thymidine ("HAT medium"), which prevent the growth of HGPRT-deficient cells.

[0542] Preferred immortalized cell lines are those that effectively fuse, support stable high-level expression of antibodies by selected antibody-producing cells, and are sensitive to culture media such as HAT culture media. Preferred immortalized cell lines are mouse myeloma lines, which can be obtained, for example, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of monoclonal antibodies. (See Kozbor, J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63)).

[0543] The culture medium of wherein cultivating hybridoma cell can subsequently determine the presence of monoclonal antibody for antigen.Preferably, the binding specificity of the monoclonal antibody produced by hybridoma cell is measured by immunoprecipitation or by in vitro binding determination such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).Such technology and determination are known in the art.The binding affinity of monoclonal antibody can be measured by Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).In addition, in the therapeutic application of monoclonal antibody, it is important to identify the antibody with high specificity and high binding affinity to target antigen.

[0544] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Goding, Monoclonal Antibodies:Principles and Practice , Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's modified Eagle's medium and RPMI-1640 medium. Alternatively, hybridoma cells can be grown in vivo in mammals as ascites.

[0545] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0546] Monoclonal antibodies can also be prepared by recombinant DNA methods such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the present invention can be easily separated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of mouse antibodies). The hybridoma cells of the present invention are used as a preferred source of such DNA. Once separated, the DNA can be placed into an expression vector, which is then transfected into a host cell such as a monkey COS cell, a Chinese hamster ovary (CHO) cell, or a myeloma cell that does not produce immunoglobulins in addition, to obtain the synthesis of monoclonal antibodies in recombinant host cells. DNA can also be modified, for example, by replacing homologous mouse sequences with coding sequences of human heavy and light chain constant domains (see U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently linking to the coding sequence of all or part of a non-immunoglobulin polypeptide of an immunoglobulin coding sequence. Such non-immunoglobulin polypeptides can replace the constant domains of an antibody of the invention, or can replace the variable domains of one antigen combining site of an antibody of the invention to create a chimeric bivalent antibody.

[0547] The monoclonal antibodies of the present invention include humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without causing an immune response by humans to the administered immunoglobulin. The humanized form of the antibody is a chimeric immunoglobulin, an immunoglobulin chain or a fragment thereof that mainly comprises a sequence of a human immunoglobulin and contains a minimal sequence derived from a non-human immunoglobulin (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of an antibody). Humanization is carried out, for example, by replacing the corresponding sequence of a human antibody with a rodent CDR or CDR sequence according to the method of Winter and colleagues (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)). (See also U.S. Patent No. 5,225,539). In some cases, the Fv framework residues of a human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies also include residues not found in, for example, CDR or framework sequences of receptor antibodies or inputs. Typically, humanized antibodies include substantially all, at least one and typically two variable domains, wherein all or substantially all CDR regions correspond to those of non-human immunoglobulins and all or substantially all framework regions are those of human immunoglobulin consensus sequences. Humanized antibodies optimally also include at least a portion of an immunoglobulin constant region (Fc), typically the Fc of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr.Op.Struct.Biol., 2:593-596 (1992)).

[0548] A fully human antibody is an antibody molecule in which the entire sequence of both the light chain and the heavy chain, including CDRs, is derived from human genes. Such antibodies are referred to herein as "human antibodies" or "fully human antibodies". Monoclonal antibodies can be prepared using tri-hybridoma technology; human B cell hybridoma technology (see Kozbor, et al., 1983 Immunol Today 4: 72); and EBV hybridoma technology to produce monoclonal antibodies (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Monoclonal antibodies are available and can be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B cells in vitro with Epstein-Barr virus (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

[0549] In addition, human antibodies can also be produced using other technologies including phage display libraries. (See Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals, such as mice in which endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which is similar to that seen in humans in all aspects, including gene rearrangement, assembly, and antibody repertoires. This method is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al., Bio / Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

[0550] Human antibodies can also be produced using transgenic non-human animals (which are modified to produce fully human antibodies in response to antigenic attack rather than endogenous antibodies of the animal). (See PCT Publication WO94 / 02602). The endogenous genes encoding heavy and light immunoglobulin chains in the non-human host have been disabled, and the active sites encoding human heavy and light chain immunoglobulins are inserted into the host genome. For example, yeast artificial chromosomes containing the necessary human DNA segments are used to incorporate human genes. Animals that provide all the desired modifications are then obtained as offspring by hybridizing intermediate transgenic animals containing less than all the modifications. An example of such a non-human animal is a so-called Xenomouse as disclosed in PCT Publications WO 96 / 33735 and WO 96 / 34096. TMThe animal produces B cells that secrete fully human immunoglobulins. Antibodies can be obtained directly from the animal after immunization with the target immunogen, for example as a preparation of polyclonal antibodies, or alternatively from immortalized B cells derived from the animal, such as hybridomas that produce monoclonal antibodies. In addition, genes encoding immunoglobulins with human variable regions can be recovered and expressed to directly obtain antibodies, or can be further modified to obtain analogs of antibodies, such as, for example, single-chain Fv (scFv) molecules.

[0551] An example of a method for producing a non-human host (exemplified by a mouse) lacking expression of endogenous immunoglobulin heavy chains is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method comprising deleting a J segment gene from at least one endogenous heavy chain locus in an embryonic stem cell to prevent locus rearrangement and to prevent the formation of transcripts of the rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and generating a transgenic mouse whose somatic cells and germ cells both contain a gene encoding a selectable marker from an embryonic stem cell.

[0552] One method of producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. The method comprises introducing an expression vector containing a nucleotide sequence encoding a heavy chain into a mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing a heavy chain and a light chain.

[0553] In a further refinement of this procedure, methods for identifying clinically relevant epitopes on immunogens and related methods for selecting antibodies that specifically bind to the relevant epitopes with high affinity are disclosed in PCT Publication WO 99 / 53049.

[0554] The antibody can be expressed from a vector containing a DNA segment encoding the single-chain antibody described above.

[0555] These may include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene guns, catheters, etc. Vectors include chemical conjugates such as those described in WO 93 / 64701, which have a targeting portion (e.g., a ligand for a cell surface receptor), and a nucleic acid binding portion (e.g., polylysine), viral vectors (e.g., DNA or RNA viral vectors), fusion proteins such as those described in PCT / US95 / 02140 (WO 95 / 22618), which are fusion proteins containing a targeting portion (e.g., an antibody specific for a target cell) and a nucleic acid binding portion (e.g., protamine), plasmids, phages, etc. Vectors may be chromosomal, non-chromosomal, or synthetic.

[0556] Preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include Moloney murine leukemia virus. DNA viral vectors are preferred. These vectors include pox vectors such as smallpox or avipox vectors, herpes virus vectors such as herpes simplex virus I (HSV) vectors (see Geller, AI et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, AI et al., Proc Natl. Acad. Sci.: USA 90:7603 (1993); Geller, AI, et al., Proc Natl. Acad. Sci USA 87:1149 (1990), adenovirus vectors (see LeGalLaSalle et al., Science, 259:988 (1993); Davidson, et al., Nat. Genet 3:219 (1993); Yang, et al., J. Virol. 69:2004 (1995) and adeno-associated virus vectors (see Kaplitt, MG et al., Nat. Genet. 8:148 (1994).

[0557] Poxvirus vectors introduce genes into the cytoplasm. Fowlpoxvirus vectors result in only short-term expression of nucleic acids. Adenovirus vectors, adeno-associated virus vectors, and herpes simplex virus (HSV) vectors are preferred for introducing nucleic acids into neural cells. Adenovirus vectors result in shorter-term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The specific vector selected will depend on the target cells and the conditions of the treatment. Introduction can be by standard techniques such as infection, transfection, transduction or transformation. Examples of modes of gene transfer include, for example, naked DNA, CaPO4 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.

[0558] Vectors can be used to target essentially any desired target cell. For example, stereotactic injection can be used to direct vectors (e.g., adenovirus, HSV) to a desired location. In addition, microparticles can be delivered by intracerebroventricular (icv) infusion using a micropump infusion system such as the SynchroMed Infusion System. Methods based on overall flow (called convection) have also been shown to be effective in delivering macromolecules to extended areas of the brain and can be used to deliver vectors to target cells. (See Bobo et al., Proc. Natl. Acad. Sci. USA 91: 2076-2080 (1994); Morrison et al., Am. J. Physiol. 266: 292-305 (1994)). Other methods that can be used include catheter, intravenous, parenteral, intraperitoneal and subcutaneous injections, and oral or other known routes of administration.

[0559] Bispecific antibodies are antibodies that have binding specificities for at least two different antigens. In the present invention, one of the binding specificities is for a target such as CD47 or any fragment thereof. The second binding target is any other antigen, and advantageously is a cell surface protein or receptor or receptor subunit.

[0560] Methods for preparing bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain / light chain pairs, wherein the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Due to the random distribution of immunoglobulin heavy chains and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually completed by an affinity chromatography step. Similar procedures are disclosed in WO93 / 08829, disclosed on May 13, 1993, and disclosed in Traunecker et al., EMBO J., 10:3655-3659 (1991).

[0561] The bispecific and / or monovalent antibodies of this aspect can be prepared using any of a variety of techniques recognized in the art, including those disclosed in co-pending application WO 2012 / 023053 filed on August 16, 2011 (the contents of which are incorporated herein by reference in their entirety). The method described in WO 2012 / 023053 generates bispecific antibodies structurally identical to human immunoglobulins. Such molecules consist of two copies of a unique heavy chain polypeptide, a first light chain variable region fused to a constant κ domain, and a second light chain variable region fused to a constant λ domain. Each binding site displays different antigenic specificities contributed by heavy and light chains. The light chain variable region can be a λ or κ family, and is preferably fused to λ and κ constant domains, respectively. This is preferred to avoid generating non-natural polypeptide joints. However, the bispecific antibodies of the present invention can also be obtained by fusing a κ light chain variable domain to a constant λ domain (for a first specificity) and fusing a λ light chain variable domain to a constant κ domain (for a second specificity). The bispecific antibodies described in WO 2012 / 023053 are called IgGκλ antibodies or "κλ bodies", a new fully human bispecific IgG format. The κλ body format allows affinity purification of bispecific antibodies that are indistinguishable from standard IgG molecules with characteristics that are indistinguishable from standard monoclonal antibodies and are therefore advantageous when compared to previous formats.

[0562] The necessary step of the method is to identify two antibody Fv regions (each consisting of a variable light chain and a variable heavy chain domain) with different antigen specificities that share the same heavy chain variable domain. A variety of methods have been described to generate monoclonal antibodies and fragments thereof. (See, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). A fully human antibody is an antibody molecule in which the sequences of both the light chain and the heavy chain include CDR 1 and 2, all from human genes. The CDR3 region can be of human origin or designed by a synthetic method. Such antibodies are referred to herein as "human antibodies" or "fully human antibodies". Human monoclonal antibodies can be prepared using tri-hybridoma technology; human B cell hybridoma technology (see Kozbor, et al., 1983 Immunol Today 4: 72); and EBV hybridoma technology to produce human monoclonal antibodies (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies can be used and can be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B cells in vitro with Epstein-Barr virus (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

[0563] For example, monoclonal antibodies are generated by immunizing an animal with a target antigen or an immunogenic fragment, derivative, or variant thereof. Alternatively, an animal is immunized with a cell transfected with a vector containing a nucleic acid molecule encoding the target antigen so that the target antigen is expressed and binds to the surface of the transfected cell. A variety of techniques for producing xenogeneic non-human animals are well known in the art. For example, see U.S. Patent Nos. 6,075,181 and 6,150,584, which are incorporated herein by reference in their entirety.

[0564] Alternatively, antibodies are obtained by screening a library containing antibodies or antigen binding domain sequences that bind to the target antigen. The library is prepared, for example, in phage as a protein or peptide fusion with a phage coat protein expressed on the surface of the assembled phage particle and a coding DNA sequence contained within the phage particle (i.e., a "phage display library").

[0565] The hybridomas produced by myeloma / B cell fusion are then screened for reactivity to the target antigen. Monoclonal antibodies are prepared, for example, using hybridoma methods such as those described by Kohler and Milstein, Nature, 256:495 (1975). In the hybridoma method, mice, hamsters or other suitable host animals are usually immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.

[0566] Although not strictly impossible, the accidental identification of different antibodies with the same heavy chain variable domain but for different antigens is highly unlikely. In fact, in most cases, the heavy chain makes most of the contribution to the antigen binding surface and is also the most variable in sequence. Specifically, the CDR3 on the heavy chain is the most different CDR in sequence, length and structure. Therefore, two antibodies specific to different antigens will almost certainly carry different heavy chain variable domains.

[0567] The method disclosed in co-pending application WO 2012 / 023053 overcomes this limitation, and greatly promotes the separation of antibodies with the same heavy chain variable domain by using an antibody library, in which the heavy chain variable domain is the same for all library members and therefore diversity is limited to the light chain variable domain. Such libraries are described, for example, in co-pending applications WO 2010 / 135558 and WO 2011 / 084255, each of which is incorporated herein by reference in its entirety. However, because the light chain variable domain is co-expressed with the heavy chain variable domain, both domains can contribute to antigen binding. In order to further promote the method, an antibody library containing the same heavy chain variable domain and various lambda variable light chains or kappa variable light chains can be used in parallel to select antibodies for different antigens in vitro. The method can identify two antibodies with a common heavy chain but one carrying lambda light chain variable domain and the other carrying kappa light chain variable domain (which can be used as a structural unit for generating a bispecific antibody in the form of a complete immunoglobulin of the present invention). The bispecific antibodies of the present invention can be of different isotypes and their Fc portions can be modified to change the binding properties to different Fc receptors and to modify the effector functions and pharmacokinetic properties of the antibodies in this way. Various methods for modifying the Fc portion have been described and can be applied to the antibodies of the present invention. (See, for example, Strohl, WR Curr Opin Biotechnol 2009 (6): 685-91; U.S. Patent No. 6,528,624; PCT / US2009 / 0191199 filed on January 9, 2009). The methods of the present invention can also be used to generate bispecific antibodies and antibody mixtures in the form of F(ab')2 lacking the Fc portion.

[0568] A common heavy chain and two different light chains are co-expressed into a single cell to allow assembly of the bispecific antibodies of the invention. If all polypeptides are expressed at the same level and assemble equally well to form immunoglobulin molecules, then the ratio of monospecific (same light chain) to bispecific (two different light chains) should be 50%. However, it is possible that different light chains are expressed at different levels and / or are not assembled with the same efficiency. Therefore, methods for regulating the relative expression of different polypeptides are used to compensate for their inherent expression characteristics or different tendencies to assemble with a common heavy chain. This regulation can be achieved through promoter strength, the use of internal ribosome entry sites (IRES) characterized by different efficiencies, or other types of regulatory elements (which can act at the transcription or translation level and on mRNA stability). Different promoters of different strengths can include CMV (immediate early cytomegalovirus promoter); EF1-1α (human elongation factor 1α-subunit promoter); Ubc (human ubiquitin C promoter); SV40 (simian virus 40 promoter). Different IRES from mammalian and viral origins have also been described. (See, e.g., Hellen CU and Sarnow P. Genes Dev 2001 15:1593–612). These IRESs can vary greatly in length and ribosome recruitment efficiency. In addition, activity can be further adjusted by introducing multiple copies of the IRES (Stephen et al. 2000 Proc Natl Acad Sci USA 97:1536-1541). Regulation of expression can also be achieved by multiple consecutive transfections of cells to increase the copy number of each gene expressing one or the other light chain and thereby modifying its relative expression. The examples provided herein demonstrate that controlling the relative expression of different chains is crucial for maximizing the assembly and overall yield of bispecific antibodies.

[0569] The co-expression of heavy chain and two light chains generates a mixture of three different antibodies into the cell culture supernatant: two monospecific bivalent antibodies and a bispecific bivalent antibody. The latter must be purified from the mixture to obtain the target molecule. The method described herein greatly promotes the purification procedure by using an affinity chromatography medium (its specificity interacts with κ or λ light chain constant domains such as CaptureSelect Fabκ and CaptureSelect Fabλ affinity matrices (BAC BV, Holland)). This multi-step affinity chromatography purification method is effective and generally applicable to the antibody of the present invention. This is in stark contrast to a specific purification method, which must be developed and optimized for each bispecific antibody derived from a cell hybridoma or other cell line expressing an antibody mixture. In fact, if the biochemical characteristics of the different antibodies in the mixture are similar, it may be challenging to separate them using standard chromatography techniques such as ion exchange chromatography, or it may not be possible at all.

[0570] Other suitable purification methods include those disclosed in co-pending application PCT / IB2012 / 003028 filed on October 19, 2012, disclosed as WO2013 / 088259, the contents of which are incorporated herein by reference in their entirety.

[0571] In other embodiments of producing bispecific antibodies, antibody variable domains (antibody-antigen binding sites) with desired binding specificity can be fused to immunoglobulin constant domain sequences. The fusion preferably has an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have a first heavy chain constant region (CH1) containing a site necessary for light chain binding present in at least one fusion. The DNA encoding the immunoglobulin heavy chain fusion and (as desired) immunoglobulin light chain are inserted into separate expression vectors and cotransfected into a suitable host organism. For further details on generating bispecific antibodies, see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0572] According to another method described in WO 96 / 27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of the heterodimer that will be recovered from recombinant cell culture.Preferred interfaces include at least a portion of the CH3 region of antibody constant domains.In this method, one or more little amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (such as tyrosine or tryptophan).The same or similar size of compensation " cavity " (Compensatory " cavities ") to large side chains is produced on the interface of the second antibody molecule by replacing large amino acid side chains with smaller amino acid side chains (such as alanine or threonine).This provides a mechanism to improve the productivity of heterodimers relative to other undesirable end products such as homodimers.

[0573] The technology of generating bispecific antibodies from antibody fragments has been described in the literature. For example, bispecific antibodies can be prepared using chemical bonds. The generated bispecific antibodies can be used as reagents for selective immobilization of enzymes.

[0574] A variety of techniques for directly preparing and isolating bispecific antibody fragments from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547-1553 (1992). Leucine zipper peptides from Fos and Jun proteins are linked to the Fab' portions of two different antibodies by gene fusion. Antibody homodimers are reduced in the hinge region to form monomers and then reoxidized to form antibody heterodimers. This method can also be used to produce antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) has provided an alternative mechanism for preparing bispecific antibody fragments. The fragments contain a light chain variable domain (V L ) is connected to the heavy chain variable domain (V H ), the linker is too short to allow pairing between two domains on the same chain. H and V L The domain is forced to align with the complementary V L and V H The domains pair to form two antigen binding sites. Another strategy for preparing bispecific antibody fragments by using single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol. 152:5368 (1994).

[0575] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

[0576] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates from a protein antigen of the present invention. Alternatively, the anti-antigen arm of an immunoglobulin molecule can be combined with an Fc receptor (FcγR) such as a T cell receptor molecule (e.g., CD2, CD3, CD28, or B7) or IgG on a leukocyte, such as FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) arm combination, to focus cellular defense mechanisms on cells expressing specific antigens. Bispecific antibodies can also be used to direct cytotoxic agents to cells expressing specific antigens. These antibodies have an antigen binding arm and an arm in conjunction with a cytotoxic agent or a radionuclide chelator such as EOTUBE, DPTA, DOTA, or TETA. Another purpose bispecific antibody binds to a protein antigen as described herein and also binds to tissue factor (TF).

[0577] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently linked antibodies. Such antibodies have been proposed, for example, to target immune system cells to unwanted cells (see U.S. Patent No. 4,676,980) and for the treatment of HIV infection (see WO 91 / 00360; WO 92 / 200373; EP 03089). It should be considered that antibodies can be prepared in vitro using known methods in synthetic protein chemistry (including those involving cross-linking agents). For example, immunotoxins can be constructed using disulfide exchange reactions or by forming thioether bonds. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed in, for example, U.S. Patent No. 4,676,980.

[0578] It may be desirable to modify the antibodies of the invention in terms of effector function to enhance, for example, the effectiveness of the antibodies in treating cancer and / or other diseases or conditions associated with abnormal CD47 expression and / or activity. For example, one or more cysteine ​​residues may be introduced into the Fc region, thereby allowing interchain disulfide bonds to form in the region. The homodimeric antibodies thus generated may have improved internalization capabilities and / or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). (See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992)). Alternatively, antibodies with dual Fc regions may be engineered and thus have enhanced complement lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989)).

[0579] The invention also relates to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a toxin (eg, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof) or a radioactive isotope (ie, a radioconjugate).

[0580] Enzymatically active toxins or fragments thereof that can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, tricothecenes. A variety of radionuclides can be used to produce radioconjugated antibodies. Examples include 212 Bi, 131 I. 131 In, 90 Y, and 186 Re.

[0581] Conjugates of antibodies and cytotoxic agents are prepared using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimide HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as benzyl (tolyene) 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelator for conjugating radionuclides to antibodies (see WO94 / 11026).

[0582] One of ordinary skill in the art will recognize that there are many possible moieties that can be coupled to the antibodies obtained in the present invention (see, for example, "Conjugate Vaccines", Contributions to Microbiology and Immunology, JM Cruse and RE Lewis, Jr (eds), Carger Press, New York, (1989), the entire contents of which are incorporated herein by reference).

[0583] Coupling can be accomplished by any chemical reaction that will bind two molecules as long as the antibody and other parts retain their respective activities. The connection can include many chemical mechanisms, such as covalent bonding, affinity bonding, embedding, coordination bonding and complexing. However, preferred bonding is covalent bonding. Covalent bonding can be achieved by direct condensation of the side chains present or by incorporation of external bridging molecules. Many divalent or multivalent linking agents can be used to couple protein molecules, such as antibodies of the present invention, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzene and cyclohexanediamine. This list is not intended to exclude various types of coupling agents known in the art, but rather exemplifies more common coupling agents. (See Killen and Lindstrom, Jour. Immun. 133:1335-2549 (1984); Jansen et al., Immunological Reviews 62:185-216 (1982); and Vitetta et al., Science 238:1098 (1987).

[0584] Preferred linkers are described in the literature. (See, e.g., Ramakrishnan, S. et al., Cancer Res. 44:201-208 (1984), which describes the use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also U.S. Pat. No. 5,030,719, which describes the use of halogenated acetyl hydrazide derivatives coupled to antibodies via oligopeptide linkers. Particularly preferred linkers include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4-succinimidyloxycarbonyl-α-methyl-α-(2-pyridyl (pridyl)-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyl dithio) propionamido] hexanoate (Pierce Chem. Co., Cat. (21558G)); (iv) SPDP (succinimidyl-6 [3-(2-pyridyl dithio) propionamido] hexanoate (Pierce Chem. Co., Cat. (21558G)); #21651G); (iv) sulfo-LC-SPDP (sulfosuccinimidyl 6 [3-(2-pyridyldithio)-propionamido] hexanoate (Pierce Chem. Co. Cat. #2165-G); and (v) sulfo-NHS (N-hydroxysulfo-succinimide: Pierce Chem. Co., Cat. #24510) conjugated to EDC.

[0585] The above-mentioned joints contain components with different properties, thus resulting in conjugates with different physicochemical properties. For example, thio-NHS esters of alkyl carboxylates are more stable than thio-NHS esters of aromatic carboxylates. NHS-esters containing joints have lower solubility than thio-NHS esters. In addition, the joint SMPT contains sterically hindered disulfide bonds and can form conjugates with increased stability. Disulfide bonds are generally more unstable than other bonds because disulfide bonds are cut in vitro, resulting in less available conjugates. Especially thio-NHS can enhance the stability of carbodiimide coupling. When used together with thio-NHS, carbodiimide coupling (such as EDC) forms esters that are more resistant to hydrolysis than separate carbodiimide coupling reactions.

[0586] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing antibodies are prepared by methods known in the art, such as Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and described in U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

[0587] Particularly useful liposomes are generated by reverse evaporation of a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). The liposomes are extruded through a filter of defined pore size to produce liposomes with a desired diameter. The Fab' fragments of the antibodies of the present invention can be conjugated to liposomes via a disulfide exchange reaction as described in Martin et al., J. Biol. Chem., 257:286-288 (1982).

[0588] Uses of Anti-CD47 x Anti-MSLN Antibodies

[0589] It will be understood that the therapeutic entities administered according to the present invention will be administered with suitable carriers, excipients, and other agents (which are incorporated into the formulation to provide improved transfer, delivery, tolerance, etc.). A variety of suitable formulations can be found in formularies known to all pharmacists: Remington's Pharmaceutical Sciences (15th edition, Mack Publishing Company, Easton, PA (1975)), especially Chapter 87 by Blaug, Seymour therein. These formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids (lipids), lipids (cationic or anionic) containing vesicles (such as Lipofectin™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsion polyethylene glycol (polyethylene glycol of various molecular weights), semisolid gels, and semisolid mixtures containing polyethylene glycol. Any of the foregoing mixtures can be suitable in treatment and therapy according to the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation, and the formulation is physiologically compatible and tolerable with the route of administration. See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." Regul. Toxicol Pharmacol. 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." Int. J. Pharm. 203(1-2):1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." J Pharm Sci. 89(8):967-78 (2000), Powell et al. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol. 52:238-311 (1998) and references therein for additional information on formulations, excipients, and carriers familiar to pharmaceutical chemists.

[0590] The therapeutic formulations of the invention (which include antibodies of the invention) are used to treat or alleviate symptoms associated with cancer, such as, but not limited to, leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung and bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, bladder cancer, kidney cancer and renal pelvic cancer, oral and pharyngeal cancer, uterine body cancer, and / or melanoma. The invention also provides methods for treating or alleviating symptoms associated with cancer. The treatment regimen is performed by identifying a subject, such as a human subject having cancer (or at risk of developing cancer), using standard methods.

[0591] The effectiveness of the treatment is determined in conjunction with any known methods for diagnosing or treating the particular immune-related disorder. Alleviation of one or more symptoms of the immune-related disorder indicates that the antibody confers a clinical benefit.

[0592] Methods for screening antibodies with the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immune-mediated techniques known in the art.

[0593] Antibodies directed against targets such as CD47, mesothelin, or a combination thereof (or fragments thereof) can be used in methods known in the art related to the localization and / or quantification of these targets, e.g., for measuring the levels of these targets in suitable physiological samples, for diagnostic methods, for imaging proteins, etc.). In a given embodiment, any specific antibody against these targets, or a derivative, fragment, analog or homolog thereof (which contains an antibody-derived antigen binding domain) is used as a pharmaceutically active compound (hereinafter referred to as a "therapeutic agent").

[0594] The antibodies of the present invention can be used to isolate specific targets using standard techniques such as immunoaffinity, chromatography or immunoprecipitation. The antibodies of the present invention (or fragments thereof) can be used diagnostically to monitor protein levels in tissues as part of a clinical testing program, for example to determine the effectiveness of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically cross-linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, radiates, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable radiate complexes include streptavidin / biotin and avidin / biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazineamine fluorescein, dansyl chloride, or phycoerythrin; examples of luminescent materials include luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include 125 I. 131 I. 35 S or 3 H.

[0595] The antibodies of the present invention, including polyclonal, monoclonal, humanized and fully human antibodies, can be used as therapeutic agents. Such agents will generally be used to treat or prevent diseases or pathologies associated with abnormal expression or activation of a given target in a subject. An antibody preparation, preferably one with high specificity and high affinity for its target antigen, is administered to a subject and will generally have an effect due to its binding to the target. Administration of antibodies can eliminate or inhibit or interfere with the signaling function of the target. Administration of antibodies can eliminate or inhibit or interfere with the binding of a target to an endogenous ligand (the target naturally binds to the ligand). For example, the antibody binds to the target and neutralizes or otherwise inhibits the interaction between CD47 and SIRPα.

[0596] The therapeutically effective amount of the antibody of the present invention generally relates to the amount required to achieve the therapeutic goal. As noted above, this can be a binding interaction between the antibody and its target antigen, which interferes with the function of the target in some cases. The amount required to be administered will also depend on the binding affinity of the antibody to its specific antigen, and also on the rate at which the administered antibody is depleted of the free volume of other subjects to which it is administered. The usual range of therapeutically effective doses of the antibody or antibody fragment of the present invention can be, but is not limited to, about 0.1 mg / kg body weight to about 50 mg / kg body weight. The usual frequency of administration can range, for example, from twice a day to once a week.

[0597] The antibodies or fragments thereof of the present invention can be administered in the form of pharmaceutical compositions for the treatment of a variety of diseases and disorders. Principles and considerations for preparing such compositions and guidance for selecting components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., ed.) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

[0598] When using antibody fragments, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based on the variable region sequence of the antibody, a peptide molecule that retains the ability to bind to the target protein sequence can be designed. Such peptides can be chemically synthesized and / or produced by recombinant DNA technology. (See, for example, Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)). The preparation may also contain more than one active compound necessary for the specific indication to be treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may include agents that enhance its function, such as, for example, cytotoxic agents, cytokines, chemotherapeutic agents, or growth inhibitors. Such molecules are suitably present in an effective amount combination for the intended purpose.

[0599] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions.

[0600] Preparations to be used for in vivo administration must be sterile. This can be easily achieved by filtering through sterile membranes.

[0601] Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibody in the form of shaped articles such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactic acid (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. Although polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can release molecules for more than 100 days, certain hydrogels release proteins for shorter periods of time.

[0602] The antibodies according to the invention can be used as reagents for detecting the presence of a given target (or a protein fragment thereof) in a sample. In some embodiments, the antibody contains a detectable label. The antibody is polyclonal, or more preferably, monoclonal. The use of intact antibodies or fragments thereof (e.g., F ab , scFv, or F (ab)2). The term "labeled" with respect to a probe or antibody is intended to encompass direct labeling of a probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin so that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells, and biological fluids separated from a subject, as well as tissues, cells, and fluids present in a subject. Thus, included in the use of the term "biological sample" are blood and fractions or components of blood, including serum, plasma, or lymph. That is, the detection method of the present invention can be used for in vitro and in vivo detection of analyte mRNA, protein, or genomic DNA in a biological sample. For example, in vitro techniques for detecting analyte mRNA include Northern hybridization and in situ hybridization. In vitro techniques for detecting analyte proteins include enzyme-linked immunosorbent assay (ELISA), protein blotting, immunoprecipitation, and immunofluorescence. In vitro techniques for detecting analyte genomic DNA include Southern hybridization. The procedure for performing immunoassays is described, for example, in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, JR Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. In addition, in vivo techniques for detecting analyte proteins include introducing labeled anti-analyte protein antibodies into a subject. For example, the antibody can be labeled with a radioactive marker, the presence or location of which in the subject can be detected by standard imaging techniques.

[0603] Pharmaceutical composition

[0604] The antibodies of the present invention (also referred to herein as "active compounds") and their derivatives, fragments, analogs and homologues can be incorporated into pharmaceutical compositions suitable for administration. Such compositions generally comprise an antibody and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents, etc., which are compatible with drug administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, which is a standard reference book in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution and 5% human serum albumin. Liposomes and non-aqueous carriers such as fixed oils can also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. In addition to any conventional media or agent range that is incompatible with the active compound, its use in the composition is contemplated. Supplementary active compounds can also be incorporated into the composition.

[0605] The pharmaceutical composition of the present invention is formulated to be compatible with the route of administration it is intended for. Examples of routes of administration include parenteral administration, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., local), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous applications may include the following components: sterile diluents such as water for injection, saline solutions, fixed oils, polyethylene glycols, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates, or phosphates and agents such as sodium chloride or glucose for adjusting tension. pH can be adjusted with acid or alkali, such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be contained in ampoules, disposable syringes, or multidose vials made of glass or plastic.

[0606] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be mobile to the extent of easy injectability. It must be stable under manufacturing and storage conditions and must be antiseptic for the contamination of microorganisms such as bacteria or fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.), and a suitable mixture thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of dispersion and by using a surfactant. The effect of preventing microorganisms can be achieved by a variety of antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents, such as sucrose, polyols such as mannitol, sorbitol, or sodium chloride, will preferably be included in the composition. The absorption of the injectable composition extension can be achieved by including an agent such as aluminum monostearate and gelatin that delays absorption in the composition.

[0607] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount into a suitable solvent having one of the ingredients listed above or a combination thereof (followed by filtration sterilization, if necessary). Typically, dispersants are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients required among those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and freeze drying, which produces a powder of the active ingredient plus any additional desired ingredients from a previously sterile filtered solution thereof.

[0608] Oral compositions generally include an inert diluent or an edible carrier. They can be contained in a gelatin capsule or compressed into a tablet. For the purpose of oral therapeutic administration, the active compound can be mixed with an excipient and used in the form of a tablet, lozenge or capsule. Oral compositions can also be prepared using a fluid carrier used as a mouthwash, wherein the compound in the fluid carrier is orally applied and gargled and spit out or swallowed. Pharmaceutically compatible adhesives and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. can contain any of the following ingredients or compounds of similar properties: adhesives such as microcrystalline cellulose, tragacanth gum or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, Primogel or corn starch; lubricants such as magnesium stearate or Sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavor enhancers such as mint, methyl salicylate or orange flavor.

[0609] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.

[0610] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, suitable penetrants for the barrier to be penetrated can be used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal use. Transmucosal administration can be completed by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels or creams generally known in the art.

[0611] The compounds may also be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0612] In one embodiment, the active compound is prepared with a carrier that will protect the compound from being quickly eliminated from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. The method for preparing such preparations will be apparent to those skilled in the art. The material can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes with monoclonal antibodies to viral antigens targeting infected cells) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art such as described in U.S. Patent number 4,522,811.

[0613] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate oral or parenteral compositions in dosage unit form. Dosage unit form, as used herein, refers to physically discrete units suitable as single dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect and the necessary pharmaceutical carrier. The specifications for the dosage unit forms of the present invention are dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved, as well as the limitations inherent in the art of formulating such active compounds for treating individuals.

[0614] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0615] The present invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. Example

[0616] Example 1: Affinity Measurement

[0617] MSLN arm. The affinity of various anti-MSLN sequences (referred to herein as MSLN arms) was determined using the Bio-Layer Interferometry (BLI) technique. An OctetRED96 instrument and a protein A biosensor (Pall, Basel, Switzerland) were used. After hydration and baseline steps, the biosensor was loaded with IgG at 1 µg / mL for 2 min in a running buffer (PBS, NaCl, Tween 20, BSA, ProClin00). Control IgG was loaded on other biosensors for reference. The biosensor was then immersed in a serial dilution of human MSLN. The expected concentration of each candidate was 100 μg / mL. K D MSLN concentration was adjusted. The biosensor was regenerated using 10 mM glycine pH 1.7. Affinity was measured by applying a 1:1 global fit model on the dual reference curve. The results are shown in Table 5 below.

[0618] Table 5: Affinity values ​​of MSLN arms (n=2)

[0619] MSLN Arm <![CDATA[ K D [nM]]]> O25 106 ± 9 O30 0.48 ± 0.03 O32 529 ± 49 O35 22.7 ± 0.5 O37 313 ± 74 O38 168 ± 23 O41 19 ± 2

[0620] Example 2: Cloning of full-length cynomolgus monkey mesothelin and expression on the cell surface.

[0621] clone. The sequence corresponding to the full-length protein cynomolgus monkey mesothelin (cMSLN) was synthesized by Eurofins and provided in the pEX-K4 vector. DNA was prepared and digested with HindIII and EcoRI restriction enzymes. The insert was gel purified twice and cloned into the pEAK8 EF1 mammalian expression vector (Edge Biosystems, Gaithersburg, MD). The construct was verified by DNA sequencing.

[0622] Express. The plasmid is then transfected into mammalian cells using a liposome-based transfection reagent such as Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA). The transfection procedure requires only a small amount of DNA and cells, typically 2 μg of plasmid DNA and 2 × 10 5cells / well, and transfection was performed in 6-well plates. Although different mammalian cell lines can be used, in the examples given below, transformed human embryonic kidney monolayer epithelial cells (PEAK cells) were transfected. These cells stably express the EBNA-1 gene, further supporting the episomal replication process, are semi-adherent and can be grown under standard conditions in a cell culture incubator (5% CO2; 37°C in DMEM medium supplemented with 10% fetal bovine serum). After 24 hours, the cells are placed under selection conditions by adding medium containing 0.5–1 μg / mL puromycin, because cells carrying episomal vectors are resistant to this antibiotic.

[0623] The cells were split in complete medium containing puromycin and used to generate a semi-stable cell line expressing cMSLN. The cell line was used for phage display selection and cell-based assays such as fluorescence associated cell sorting (FACS).

[0624] Example 3: Expression and purification of bispecific antibodies carrying λ and κ light chains

[0625] The simultaneous expression of one heavy chain and two light chains in the same cell can result in the assembly of three different antibodies. Simultaneous expression can be achieved in different ways such as transfecting multiple vectors expressing one of the chains for co-expression or by using vectors driving the expression of multiple genes. The vector pNoviκHλ was previously generated to allow the co-expression of one heavy chain, one κ light chain and one λ light chain, as described in US 2012 / 0184716 and WO 2012 / 023053, each of which is incorporated herein by reference in its entirety. The expression of the three genes is driven by the human cytomegalovirus promoter (hCMV), and the vector also contains a glutamine synthetase gene (GS) that enables the selection and establishment of stable cell lines. The VL genes of anti-hMSLN IgGλ or anti-hCD47 IgGκ were cloned in the vector pNoviκHλ for transient expression in mammalian cells. Peak cells were cultured at 8 x 10 6Concentration of cells / flask Cells were expanded and split in 45 ml of medium containing fetal bovine serum in T175 flasks. 30 μg of plasmid DNA was transfected into cells using Lipofectamine 2000 transfection reagent according to the manufacturer's instructions. Antibody concentrations in serum-containing supernatants of transfected cells were measured using Bio-Layer Interferometry (BLI) technology at several time points during production. OctetRED96 instrument and protein A biosensor were used for quantification (Pall, Basel, Switzerland). 200 μL of supernatant was used to determine IgG concentration; bioreactors were pre-conditioned and regenerated with 10 mM glycine pH 1.7, and IgG calibrators diluted in conditioned PEAK cell culture medium were prepared for standard curve generation. Concentrations were determined using the dose-response 5PL-weighted Y standard curve equation and the initial slope binding rate equation. Depending on the antibody concentration, supernatants were harvested 7-10 days after transfection and clarified by centrifugation at 1300 g for 10 minutes. The purification method consists of three affinity steps. First, CaptureSelect™ IgG-CH1 affinity matrix (ThermoFisher Scientific, Waltham, MA) was washed with PBS and then added to the clarified supernatant. After incubation overnight at +4°C, the supernatant was centrifuged at 1000 g for 10 minutes, the flow through was stored and the resin was washed twice with PBS. Subsequently, the resin was transferred to a spin column and a solution containing 50 mM glycine pH 2.7 was used for elution. Several elution fractions were generated, combined and desalted using a 50 kDa Amicon® Ultra Centrifugal filter unit (Merck KGaA, Darmstadt, Germany) against 25 mM histidine / 125 mM NaCl pH 6.0 buffer. The final product containing total human IgG from the supernatant was quantified using a Nanodrop spectrophotometer (NanoDrop Technologies, Wilmington, DE) and incubated with an appropriate volume of CaptureSelect™ LC-kappa (Hu) affinity matrix (ThermoFisherScientific, Waltham, MA) for 30 minutes at RT and 20 rpm. The incubation, resin recovery, elution, and desalting steps were performed as previously described.The final affinity purification step was performed using CaptureSelect™ LC-lambda (Hu) affinity matrix (Thermo Fisher Scientific, Waltham, MA) as applied to the previous two purification steps. The final product was quantified using Nanodrop. The purified bispecific antibodies were analyzed by electrophoresis under denaturing and reducing conditions. Agilent 2100 Bioanalyzer and Protein 80 kit (Agilent Technologies, Santa Clara, CA, USA) were used as described by the manufacturer. 4 μL of the purified sample was mixed with sample buffer supplemented with dithiothreitol (DTT; Sigma Aldrich, St.Louis, MO). The sample was heated at 95°C for 5 minutes and then loaded onto the chip. An aliquot from the first purification step (containing the bispecific antibody and two monospecific mAbs) and an aliquot of the final product were loaded on an isoelectric focusing (IEF) gel to assess the purity of the final purified bispecific antibody (without mAb contamination). Aggregate levels were determined by SEC-HPLC. Finally, OctetRED96 was used to evaluate the binding of bispecific antibodies on two targets. In short, biotinylated targets (hMSLN, hCD47 and unrelated targets) were loaded on streptavidin biosensors. The biosensor was then immersed in a solution containing the bispecific antibody and the binding was monitored in real time. All samples were tested for endotoxin contamination using the LimulusAmebocyteLysate test (LAL; Charles River Laboratories, Wilmington, MA).

[0626] Example 4: Cloning, expression and purification of human mesothelin

[0627] clone. The sequence corresponding to the extracellular domain of human mesothelin (hMSLN) (amino acids 296 to 580), followed by Avitag™ (Avidity, Denver CO) and a C-terminal hexa-histidine tag was synthesized by Eurofins and provided in the pEX-K vector. The tags allow single-site biotinylation of the protein and purification by IMAC (immobilized metal ion affinity chromatography), respectively. DNA was prepared and digested with HindIII and EcoRI restriction enzymes. The insert was gel purified twice and cloned into the pEAK8 EF1 mammalian expression vector (Edge Biosystems, Gaithersburg, MD). The construct was verified by DNA sequencing.

[0628] Express. The plasmid is then transfected into mammalian cells using a liposome-based transfection reagent such as Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA). The transfection step requires only a small amount of DNA and cells, typically 2 × 10 5 cells and 2 μg of plasmid DNA / well, and transfection was performed in 6-well plates. Although different mammalian cell lines can be used, in the examples given below, transformed human embryonic kidney monolayer epithelial cells (PEAK cells) were transfected. These cells stably express the EBNA-1 gene, further supporting the episomal replication process, are semi-adherent and can be grown in a standard condition cell culture incubator (5% CO2; 37°C in DMEM medium supplemented with 10% fetal bovine serum). After 24 hours, the cells are placed under selection conditions by adding medium containing 0.5–1 μg / mL puromycin, because cells carrying episomal vectors are resistant to this antibiotic.

[0629] Two to three weeks after transfection, the cells are used to inoculate a disposable CELLine bioreactor for the production step. For in vivo production of biotinylated proteins, 50 μM biotin is added to the culture medium. CELLine is a two-compartment bioreactor that can be used in a standard cell culture incubator. The smaller compartment (15 mL) contains cells in serum-free medium and is separated from the larger (one liter) compartment containing complete medium by a semipermeable membrane with a cutoff size of 10 kDa (Bruce et al. 2002, McDonald et al. 2005). The system allows the diffusion of nutrients, gazes, and metabolic wastes while retaining cells and secreted proteins in the smaller compartment. The culture is maintained for 7-10 days before the supernatant is harvested. Because the culture medium contains serum, the cells maintain good viability and several production runs can be performed using the same cells and containers.

[0630] purification.After harvesting, the supernatant recovered from the cell compartment of the CELLine bioreactor contains concentrated recombinant protein and low levels of contaminants, as they are unable to cross the 10 kDa membrane that separates the two compartments of the reactor. This increased recombinant protein to contaminant ratio greatly enhances the efficiency of purification using IMAC. The supernatant is clarified by centrifugation and filtration through a 0.22 µm membrane. The concentrated supernatant is then supplemented with 100 mM imidazole and loaded onto a Ni-NTA affinity chromatography resin (Qiagen). The relatively high concentration of imidazole minimizes the binding of contaminants to the resin. After washing the column, the protein is eluted on an ÄKTA Prime chromatography system (GE Healthcare, Little Chalfont, UK) using a 30 mL imidazole gradient (20–400 mM imidazole) at a flow rate of 2 mL / min. The eluted fractions can be analyzed by SDS-PAGE or ELISA to determine their content in recombinant protein. The fractions of interest are pooled and desalted on a PD-10 column (GE Healthcare) equilibrated with phosphate-buffered saline or another appropriate buffer. The desalted protein can then be quantified using a variety of techniques and its purity can be analyzed by SDS-PAGE. Recombinant hMSLN was biotinylated in vitro using biotin ligase (Avidity, Denver CO) according to the manufacturer's instructions. After desalting, the biotinylation level was assessed by pull-down assay using streptavidin magnetic beads and SDS-PAGE analysis.

[0631] Example 5: Reformatting of fixed VH candidates into IgG and transient expression in mammalian cells

[0632] After screening, scFv candidates against hMSLN or hCD47 were recombined into IgG and expressed by transient transfection into PEAK cells. The VL sequence of the selected scFv was amplified with specific oligonucleotides and cloned into an expression vector containing universal heavy and light chain constant regions. The construction was verified by sequencing. Mammalian Peak cells were grown in T75 flasks at 3 x 10 6Cells were grown at a concentration of 10 cells / flask in a humidified incubator at 37°C and 5% CO2. One day after cell splitting, expression vectors were transfected using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. Antibody concentrations in serum-containing supernatants of transfected cells were measured using Bio-Layer Interferometry (BLI) technology at several time points during production. An OctetRED96 instrument and a protein A biosensor were used for quantification (Pall, Basel, Switzerland). 200 µL of supernatant was used to determine IgG concentration; bioreactors were pre-conditioned and regenerated with 10 mM glycine pH 1.7, and IgG calibrators diluted in conditioned Peak cell culture medium were prepared for standard curve generation. Concentrations were determined using the dose-response 5PL unweighted standard curve equation and the initial slope binding rate equation. After 6-7 days of cultivation, the supernatant was harvested for IgG purification on FcXL affinity chromatography resin (ThermoFisherScientific, Waltham, MA) according to the manufacturer's instructions. In short, the supernatant from the transfected cells was incubated overnight with the resin at +4 °C. The sample was then centrifuged and the resin was transferred to a column filter for elution. The eluted IgG fraction was then desalted for PBS and quantified by the absorbance at 280 nm for IgG content. Purity and IgG integrity were verified by electrophoresis.

[0633] Example 6: Binding of MSLN monoclonal antibody and MSLN / CD47 bispecific antibody to human and cynomolgus monkey mesothelin

[0634] The ability of MSLN monoclonal antibody and MSLN / CD47 bispecific antibody to bind to human and cynomolgus monkey mesothelin expressed on the cell surface was tested by flow cytometry. CHO cells stably expressing human MSLN (CHO-huMSLN cells) or cynomolgus monkey MSLN (CHO-huMSLN cells) were used for this purpose because the anti-human CD47 antibody arm of the biAb could not recognize hamster mesothelin orthologs. In short, increasing concentrations of MSLN Mab and biAb were incubated with CHO-huMSLN cells or CHO-cyMSLN cells at 4°C for 30 minutes. After two washes, the bound antibodies were detected using a PE-conjugated anti-human Fc secondary antibody (Southern Biotech #9042-09). Untransfected CHO cells were used as controls. Figure 1Strong binding of MSLN monoclonal and bispecific antibodies to mesothelin expressed on the surface of mesothelin-transfected CHO cells was shown. All MSLN antibodies showed a high level of species cross-reactivity, as the MFI / antibody concentration curves obtained with CHO cells expressing human and cynomolgus MSLN looked very similar.

[0635] Example 7: ADCP induced by bispecific antibodies targeting MSLN and CD47.

[0636] The ability of the dual-targeted CD47 / MSLN κλ body to co-attach CD47 and MSLN on the cell surface allows neutralization of MSLN-dependent CD47-SIRPa interactions. This in turn translates into effective and selective cancer cell killing mediated by the CD47 / MSLN κλ body, as demonstrated in the ADCP experiments described in this example. ADCP was tested for three tumor cell lines expressing different levels of CD47 and MSLN: NCI-N87, HPAC, and Caov-3. The levels of cell surface expression of CD47 and mesothelin for NCI-N87 cells were 43,000 and 27,000, respectively. The levels of cell surface expression of CD47 and mesothelin for HPAC cells were 105,000 and 13,000, respectively. The levels of cell surface expression of CD47 and mesothelin for Caov-3 cells were 220,000 and 38,000, respectively. ADCP experiments were performed with human macrophages differentiated from peripheral blood monocytes. Two different assay formats were used to evaluate phagocytosis. In the experiment shown in Figure 2, macrophages were co-incubated with CFSE-labeled target cells (effector: target ratio 3: 1) at 37°C in the presence of increasing concentrations of antibodies for 2.5 hours. At the end of the incubation period, biotinylated anti-human CD1 antibodies and Strep-Cy5 were added to mark macrophages. The cells were then washed and subjected to FACS analysis. Phagocytosis was confirmed by double positive events. In the experiment shown in Figure 3, macrophages adhered to microplate wells were co-incubated with calcein AM-labeled target cells (effector: target ratio 1: 1) at 37°C in the presence of increasing concentrations of antibodies for 2.5 hours. At the end of the incubation period, the supernatant was replaced by complete culture medium, and the microplate was imaged with the CellInsight CX5 high content screening platform. 1500 macrophages were acquired and analyzed per well. Phagocytosis was demonstrated to be a double positive event, and the phagocytic index was calculated by software.

[0637] The dose-response experiments in Figure 2 demonstrate that the CD47 / MSLN BsAb phagocytoses NCI-N87 and HPAC cells in a MSLN-dependent manner, given the much lower efficiency of the CD47 monovalent antibody (i.e., the κλ body lacking the anti-MSLN arm). Figure 2 also shows that the ADCP induced by the CD47 / MSLN BsAb is more effective than the benchmark antibody, the high affinity anti-human CD47 monoclonal antibody B6H12-huIgG1, or the monoclonal anti-MSLN antibody amatuximab (KEGG ID: D09767, PubChem SID: 124490507). Figure 3 shows a comparison of ADCP with CD47 / MSLN κλ bodies with the corresponding anti-CD47 and anti-MSLN monovalent antibodies and anti-MSLN mAb. CD47 / MSLN κλ bodies induced significantly higher levels of phagocytosis of NCI-N87 and Caov-3 target cells, demonstrating that dual targeting and MSLN-mediated CD47 blockade are critical for in vitro efficacy.

[0638] Example 8: ADCC induced by bispecific antibodies targeting MSLN and CD47.

[0639] The antibody-dependent cell-mediated cytotoxicity (ADCC) of four CD47 / MSLN κλ bodies (K2O25, K2O35, K2O38, and K2O41) was evaluated using a Cr51-release cell-based assay. ADCC was tested for three tumor cell lines expressing different levels of CD47 and MSLN: NCI-N87, NCI-H226, and HepG2-MSLN. The levels of cell surface expression of CD47 and mesothelin for NCI-N87 cells were 43,000 and 27,000, respectively. The levels of cell surface expression of CD47 and mesothelin for NCI-H226 cells were 200,000 and 250,000, respectively. The levels of cell surface expression of CD47 and mesothelin for HepG2-MSLN cells (obtained by stable transfection of human mesothelin in the human hepatoma cell line HepG2) were 22,000 and 120,000, respectively. ADCC experiments were performed with whole human PBMCs and Cr51-loaded MSLN-positive target cell lines as effector cells. Briefly, target cells were loaded with Cr51 for 1 h at 37°C. After washing, cells were conditioned with CD47 / MSLN κλ bodies or MSLN benchmark mAb amatuximab for 30 min at 37°C. 5,000 Cr51-loaded target cells were then mixed with 250,000 IL-2-activated PBMC effector cells to obtain a final 50:1 ratio between effector and target cells (E:T ratio = 50) and incubated at 37°C for 4 h. After brief centrifugation (10 min at 1500 rpm), the cell-free supernatant was counted in a γ-counter. Negative controls (spontaneous Cr51 release) consisted of Cr51-loaded target cells incubated with medium in the absence of effector cells. The total lysis control consisted of Cr51-loaded target cells incubated with cell lysis solution (Triton X-100). The nonspecific lysis control (baseline) consisted of Cr51-loaded target cells incubated with effector cells without the addition of any antibody. ADCC reactions were performed in triplicate. Ab-specific ADCC percentage was calculated using the following formula: %ADCC = ((sample cpm–nonspecific lysis control cpm) / (total lysis control cpm–negative control cpm)) x 100%. Figure 4 The experiment shown in compares the effects of four CD47 / MSLN κλ bodies and the MSLN benchmark mAb amatuximab. All CD47 / MSLN κλ bodies tested showed approximately similar ADCC potency with the three cell lines. In all cases, the ADCC induced by the CD47 / MSLN κλ body was significantly higher than that of amatuximab.

[0640] Example 9: In vivo anti-tumor activity of bispecific antibodies

[0641] The anti-tumor activity of five CD47 / MSLN κλ bodies (biAb025, biAb030, biAb035, biAb038 and biAb041) was evaluated in a xenograft model. x 10 6 HepG2-MSLN cells were implanted subcutaneously into NOD / SCID mice and allowed to grow for 15 days. The mice were then randomly divided into 6 groups (7 mice per group) and antibody treatment was initiated. Antibodies were injected iv once a week until the end of the experiment (d55). Fig. 6A In the experiment shown in x10 6 OVCAR3 cells were implanted subcutaneously into NOD / SCID mice. The next day, the mice were randomly divided into 2 groups (7 mice in each group) and antibody treatment was started. Antibodies were injected iv once a week until d56. Figure 6B In the experiment shown in x 10 6 CAOV3 cells were implanted subcutaneously in NOD / SCID mice. The next day, the mice were randomly divided into 2 groups (6 or 7 mice per group) and antibody treatment was started. Antibodies were injected iv once a week until d18. All antibodies were administered at 60 mg / kg per injection. Tumor volume was measured 2 to 3 times a week and calculated using the following formula: ((length x width2) / 2). The experiment shown in Figure 5 compares the effects of CD47 / MSLN κλ body with the benchmark monoclonal antibody CD47 mAb B6H12-hIgGl and MSLN mAb amatuximab. For statistical analysis at the endpoint ( Figure 5A ), one-way ANOVA followed by multiple comparison test (Tukey's multiple comparison) was performed using GraphPad Prism. p-values: *p<0.05, **p<0.01; ns, not significant. The percentage of tumor growth inhibition (TGI) compared to the isotype control group was also determined using the following formula ( Figure 5B): %TGI = {1- [(Tt-TO) / (Vt-VO)]} x 100; where Tt = median tumor volume treated at time t; TO = median tumor volume treated at time 0; Vt = median tumor volume of control at time t, and VO = median tumor volume of control at time = 0. As shown in Figure 5, treatment with five CD47 / MSLNκλ-bodies and amatuximab, but not with CD47 mAb B6H12-hlgG1, significantly reduced tumor growth compared to the hlgG1 control. In addition, the anti-tumor efficacy of four of the five CD47 / MSLNκλ-bodies tested (all except biAb030) was superior to amatuximab, with three biAbs exhibiting TGI>90% (biAb025, biAb038, and biAb041). The experiment shown in Figure 6 shows that the biAbO38 CD47 / MSLN κλ body prevents tumor growth.

[0642] Other Implementations

[0643] Although the invention has been described in conjunction with its detailed description, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

Claims

1. An isolated bispecific antibody comprising a first arm comprising a first amino acid sequence that binds CD47 and a second arm comprising a second amino acid sequence that binds mesothelin (MSLN), wherein the bispecific antibody inhibits the interaction between CD47 and signal regulatory protein alpha (SIRPα), wherein the isolated bispecific antibody comprises: a heavy chain comprising CDRH1 consisting of the amino acid sequence of SEQ ID NO: 225, CDRH2 consisting of the amino acid sequence of SEQ ID NO: 226, and CDRH3 consisting of the amino acid sequence of SEQ ID NO: 227, A kappa light chain comprising a CDRL1 consisting of the amino acid sequence of SEQ ID NO: 240, a CDRL2 consisting of the amino acid sequence of SEQ ID NO: 242, and a CDRL3 consisting of the amino acid sequence of SEQ ID NO: 254, and a lambda light chain comprising a combination of a CDRL1 amino acid sequence, a CDRL2 amino acid sequence, and a CDRL3 amino acid sequence selected from the group consisting of: (a) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 286, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 292, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 298; (b) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 282, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 288, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 294; (c) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 283, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 289, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 295; (d) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 284, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 290, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 296; (e) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 285, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 291, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 297; (f) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 287, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 293, and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 299; or (g) CDRL1 consisting of the amino acid sequence of SEQ ID NO: 282, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 288, and CDRL3 consisting of the amino acid sequence of SEQ ID NO:

300. 2 . The isolated bispecific antibody of claim 1 , wherein the bispecific antibody inhibits the interaction between human CD47 and human SIRPα.

3. The isolated bispecific antibody of claim 1, wherein the first arm comprises: a variable heavy chain consisting of the amino acid sequence of SEQ ID NO: 114 and a variable light chain consisting of the amino acid sequence of SEQ ID NO:

168.

4. The isolated bispecific antibody of claim 1, wherein the first arm comprises: a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence of SEQ ID NO:

56.

5. The isolated bispecific antibody of claim 1, wherein the isolated bispecific antibody comprises: a variable heavy chain consisting of the amino acid sequence of SEQ ID NO: 114, and a combination of a kappa variable light chain and a lambda light chain selected from the group consisting of: (a) a kappa variable light chain consisting of the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain consisting of the amino acid sequence of SEQ ID NO: 220; (b) a kappa variable light chain consisting of the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain consisting of the amino acid sequence of SEQ ID NO: 212; (c) a kappa variable light chain consisting of the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain consisting of the amino acid sequence of SEQ ID NO: 214; (d) a kappa variable light chain consisting of the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain consisting of the amino acid sequence of SEQ ID NO: 216; (e) a kappa variable light chain consisting of the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain consisting of the amino acid sequence of SEQ ID NO: 218; (f) a kappa variable light chain comprising the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain comprising the amino acid sequence of SEQ ID NO: 222; or (g) a kappa variable light chain comprising the amino acid sequence of SEQ ID NO: 168 and a lambda variable light chain comprising the amino acid sequence of SEQ ID NO:

224.

6. The isolated bispecific antibody of claim 1, wherein the isolated bispecific antibody comprises: a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2, and a combination of a kappa light chain and a lambda light chain selected from the group consisting of: (a) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:106; (b) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:98; (c) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:100; (d) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:102; (e) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:104; (f) a kappa light chain consisting of the amino acid sequence of SEQ ID NO:56 and a lambda light chain consisting of the amino acid sequence of SEQ ID NO:108; or (g) a κ light chain consisting of the amino acid sequence of SEQ ID NO:56 and a λ light chain consisting of the amino acid sequence of SEQ ID NO:

110.

7. The isolated bispecific antibody of claim 1, wherein the bispecific antibody comprises two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first light chain and the second light chain are different.

8. The isolated bispecific antibody of claim 7, wherein at least a portion of the first light chain is of the kappa type and at least a portion of the second light chain is of the lambda type.

9. The isolated bispecific antibody of claim 8, wherein the first light chain comprises at least a kappa constant region.

10. The isolated bispecific antibody of claim 9, wherein the first light chain further comprises a kappa variable region.

11. The isolated bispecific antibody of claim 9, wherein the first light chain further comprises a lambda variable region.

12. The isolated bispecific antibody of claim 8, wherein the second light chain comprises at least a lambda constant region.

13. The isolated bispecific antibody of claim 12, wherein the second light chain further comprises a lambda variable region.

14. The isolated bispecific antibody of claim 12, wherein the second light chain further comprises a kappa variable region.

15. The isolated bispecific antibody of claim 8, wherein the first light chain comprises a kappa constant region and a kappa variable region, and wherein the second light chain comprises a lambda constant region and a lambda variable region.

16. The isolated bispecific antibody of claim 1, wherein the constant and variable framework region sequences of the bispecific antibody are human.

17. Use of the isolated bispecific antibody of any one of claims 1 to 16 in the preparation of a medicament for treating ovarian cancer, liver cancer or lung cancer.